Method for evaluating quality of neural retina for transplantation and neural retina sheet for transplantation
Patent Information
- Application Number
- JP2024106151
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-03-13
- Filing Date
- 2024-07-01
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2040-03-13
AI Technical Summary
Existing methods for evaluating the quality of neural retinas derived from pluripotent stem cells for transplantation are inadequate, as they fail to account for unintended non-neural retinal cells generated as by-products, which can compromise the efficacy of transplantation treatments for neurological diseases.
A method for evaluating neural retina quality by detecting the expression of neural retinal cell-related genes and non-neural retinal cell-related genes, such as cerebrospinal and eyeball-related tissue markers, to ensure the purity and suitability of the neural retina for transplantation.
This method allows for the selective identification and use of high-quality neural retinas for transplantation, reducing the risk of unintended tissue contamination and enhancing the effectiveness of transplantation therapies.
Smart Images

Figure 00000059_0000 
Figure 00000059_0001 
Figure 00000060_0000
Abstract
Description
[Technical field]
[0001] The present invention relates to a method for evaluating the quality of a neural retina for transplantation and a neural retina sheet for transplantation, and in particular to a method for evaluating the quality of a neural retina for transplantation derived from pluripotent stem cells and a neural retina sheet for transplantation derived from pluripotent stem cells. [Background technology]
[0002] In the nervous tissue of a living organism, one or more types of nervous system cells form a layered structure. Retinal tissue, which is one type of nervous tissue, is mainly composed of five types of nerve cells, namely photoreceptor cells, bipolar cells, horizontal cells, amacrine cells, and ganglion cells, and glial cells, forming a three-dimensional layered structure. It has been suggested that transplantation therapy using nervous tissue is effective as a treatment for neurological diseases, such as retinal degenerative diseases, but it has been difficult to obtain tissue that maintains the layered structure and function that reflects the nervous tissue of a living human body, making it difficult to generalize this as a treatment method. In recent years, it has become possible to produce nervous tissue (e.g., retinal tissue) by inducing differentiation from pluripotent stem cells (Non-Patent Documents 1, 2, 3, and 4).
[0003] Retinal tissue derived from pluripotent stem cells contains many kinds of retinal layer-specific nerve cells and is composed of layers, so it has a very complex structure. When using retinal tissue with such a very complex structure as a cell medicine for transplantation, it is particularly required to strictly control its quality. Methods for evaluating the quality of neural retina include an image analysis method that analyzes the presence or absence of a continuous epithelial structure in a cell aggregate (Patent Document 1). [Prior art documents] [Patent documents]
[0004] [Patent Document 1] WO2017 / 090741 [Non-patent literature]
[0005] [Non-Patent Document 1] Eiraku M. et al., “Self-organized Formationof Polarized Cortical Tissues From ESCs and Its Active Manipulation byExtrinsic Signals”, Cell Stem Cell, 3(5), 519-32(2008) [Non-Patent Document 2] Eiraku M. et al., “Self-organizing optic-cupmorphogenesis in three-dimensional culture”, Nature,472, 51-56(2011) [Non-Patent Document 3] Nakano T. et al., “Self-formation of OpticCups and Storable Stratified Neural Retina From Human ESCs” Cell Stem Cell, 10(6), 771-775(2012) [Non-Patent Document 4] Kawahara A. et al., “Generation of a ciliarymargin-like stem cell niche from self-organizing human retinal tissue” Nature Communications, 6, 6286(2015) Summary of the Invention [Problem to be solved by the invention]
[0006] In view of the above circumstances, an object of the present invention is to provide a method for evaluating the quality of a neural retina for transplantation and a neural retina sheet for transplantation selected by said method. [Means for solving the problem]
[0007] As a result of intensive research, the present inventors have found that in the process of producing cell aggregates containing neural retina derived from pluripotent stem cells, in addition to retina layer-specific nerve cells (target cells, neural retina-related cells), cells other than retina layer-specific nerve cells (untarget cells, non-neural retina-related cells) may be by-produced in some cell aggregates. Then, as a result of comprehensive analysis of gene expression, etc. of multiple samples, it was found that the untargeted cells that may be by-produced are cerebrospinal tissue and eye-related tissue. Furthermore, as a result of detailed analysis of cerebrospinal tissue and eye-related tissue, it was found that the telencephalon (cerebrum), diencephalon (including hypothalamus), midbrain, and spinal cord may be by-produced as cerebrospinal tissue, and the retinal pigment epithelium (RPE), ciliary body, lens, and optic stalk (optic stalk and optic nerve tissue) may be by-produced as eye-related tissue.
[0008] Based on these novel findings, the inventors have discovered that by analyzing the expression of genes associated with target cells and the expression of genes associated with non-target cells, it is possible to evaluate whether a neural retina is suitable for transplantation, and thereby to select neural retina for transplantation, thereby completing the present invention.
[0009] That is, the present invention relates to the following. [1] 1. A method for assessing the quality of a neural retina for transplantation, comprising: The above method is Extracting a part or the whole of a cell aggregate including a neural retina having an epithelial structure derived from pluripotent stem cells as a quality assessment sample; Detecting expression of neural retinal cell-related genes and non-neural retinal cell-related genes in the quality assessment sample; When expression of the neural retinal cell-related gene is observed and expression of the non-neural retinal cell-related gene is not observed, (1) The neural retina (neural retina for transplantation) in the same cell aggregate as the cell aggregate containing the quality evaluation sample, which is a part of the neural retina; (2) The above neural retina (neural retina for transplantation) in a cell aggregate from the same lot as the cell aggregate containing the quality evaluation sample, which is a part of the above, or (3) The above neural retina (neural retina for transplantation) in a cell aggregate from the same lot as the cell aggregates of the quality evaluation samples, which are all of the above. and determining that the resulting tissue can be used as a neural retina for transplantation; A method, wherein the non-neural retinal cell-related gene comprises one or more genes selected from the group consisting of cerebrospinal tissue marker genes and eye-related tissue marker genes. [2] the cerebrospinal tissue marker gene is one or more genes selected from the group consisting of a telencephalon marker gene, a diencephalon / mesencephalon marker gene, and a spinal cord marker gene; The method according to [1] above, wherein the eye-related tissue marker gene is one or more genes selected from the group consisting of an optic stalk marker gene, a ciliary body marker gene, a lens marker gene, and a retinal pigment epithelium marker gene. [3] The telencephalon marker gene comprises one or more genes selected from the group consisting of FoxG1, Emx2, Dlx2, Dlx1, and Dlx5, the diencephalon / mesencephalon marker gene comprises one or more genes selected from the group consisting of OTX1, OTX2, DMBX1, Rx, Nkx2.1, OTP, FGFR2, EFNA5 and GAD1, the spinal cord marker gene comprises one or more genes selected from the group consisting of HOXD4, HOXD3, HOXD1, HOXC5, HOXA5 and HOXB2, The Optic Stalk marker gene comprises one or more genes selected from the group consisting of GREM1, GPR17, ACVR1C, CDH6, Pax2, Pax8, GAD2 and SEMA5A, The ciliary body marker gene comprises one or more genes selected from the group consisting of Zic1, MAL, HNF1beta, FoxQ1, CLDN2, CLDN1, GPR177, AQP1, and AQP4; The lens marker gene comprises one or more genes selected from the group consisting of CRYAA and CRYBA1, The method according to [2] above, wherein the retinal pigment epithelium marker gene comprises one or more genes selected from the group consisting of MITF, TTR and BEST1. [4] The method according to any one of [1] to [3] above, wherein the non-neural retinal cell-related genes further include an undifferentiated pluripotent stem cell marker gene. [5] The method according to [4] above, wherein the undifferentiated pluripotent stem cell marker gene comprises one or more genes selected from the group consisting of Oct3 / 4, Nanog and lin28. [6] The method according to any of [1] to [5] above, wherein cell aggregates from the same lot as the cell aggregates of the quality assessment sample are cell aggregates produced under conditions that show a gene expression profile equivalent to that of the neural retina for transplantation. [6-1] The method according to any one of [1] to [6] above, wherein the neural retina for transplantation comprises the central portion of an epithelial tissue. [6-2] The method according to any one of [1] to [6] and [6-1] above, wherein the neural retina for transplantation is a continuous epithelial tissue. [7] The quality assessment sample is a part of a cell aggregate, The method according to any of [1] to [6] above, in which, when expression of the neural retinal cell-related genes is observed and expression of the non-neural retinal cell-related genes is not observed, it is determined that the neural retina that is at least partially continuous with or adjacent to the part of the cell aggregate that contains the quality assessment sample, which is the part, can be used as a neural retina for transplantation. [8] The method according to [7] above, wherein the neural retina for transplantation is contained in the same epithelial tissue as the quality assessment sample. [9] The method according to [8] above, wherein the neural retina for transplantation comprises a central portion of the same epithelial tissue.
[10] The method according to [9] above, wherein the neural retina for transplantation is a continuous epithelial tissue.
[11] the cell aggregate containing the neural retina comprises a first epithelial tissue containing the neural retina for transplantation, and a second epithelial tissue having a continuity of the slope of the tangent of a surface different from the continuity of the slope of the tangent of the surface of the first epithelial tissue and containing a non-neural retinal cell; the neural retina for transplantation includes an area on the first epithelium furthest from the second epithelium; The method according to any one of [7] to
[10] above, wherein the quality assessment sample is a portion present between the second epithelial tissue and the neural retina for transplantation.
[12] The method according to
[11] above, wherein the second epithelial tissue is eye-related tissue and / or cerebrospinal tissue.
[13] The method according to
[12] above, wherein the eye-related tissue comprises retinal pigment epithelial cells and the ciliary body.
[14] The method according to any one of [1] to
[13] above, wherein the detection of expression of the neural retinal cell-associated gene and the non-neural retinal cell-associated gene is carried out by quantitative PCR.
[15] The method according to
[14] above, comprising determining that the tissue can be used as a neural retina for transplantation if the tissue satisfies the following criteria 1 and 2. Criterion 1: The difference (ΔCt value) between the threshold cycle (Ct) value of the neural retinal cell-related gene and the Ct value of the internal standard gene is 10 or less. Criterion 2: The difference (ΔCt value) between the Ct value of the non-neural retinal cell-related gene and the Ct value of the internal control gene is 5 or more.
[16] The method according to
[14] or
[15] above, wherein the quantitative PCR is carried out by a method including the steps (1) to (5) below, thereby simultaneously detecting the expression levels of each of neural retinal cell-related genes and non-neural retinal cell-related genes in two or more of the quality assessment samples. (1) preparing a flow path plate having a sample well group consisting of one group of 8 to 800 independent sample wells, a primer well group consisting of one or more groups of 8 to 800 independent primer wells, and flow paths connecting the independent sample wells in the sample well group and the independent primer wells in each primer well group, a solution containing nucleic acid obtained from two or more of the above quality assessment samples (sample solution), and a solution containing one or more primers specific to one or more of the above neural retinal cell-related genes or the above non-neural retinal cell-related genes (primer solution); (2) adding the sample solution to each of the quality evaluation samples in a sample well group so that one sample solution per one sample well is added; (3) adding the primer solution to one or more primer wells in the one or more primer well groups so that the primer well groups are different; (4) separately mixing the primer with the nucleic acid through the flow path; and (5) Perform quantitative PCR using the mixture obtained in (4).
[17] A neural retinal sheet comprising: (1) Derived from pluripotent stem cells; (2) has a three-dimensional structure; (3) A neural retina layer having a multi-layer structure including a photoreceptor layer and an inner layer, (4) The photoreceptor layer includes one or more cells selected from the group consisting of photoreceptor precursor cells and photoreceptor cells, (5) The inner layer comprises one or more cells selected from the group consisting of retinal progenitor cells, ganglion cells, amacrine cells, and bipolar cells; (6) the surface of the neural retinal layer has an apical surface; (7) the inner layer is present inside the photoreceptor layer present along the apical surface, (8) The area of the neural retinal layer is 50% or more of the total area of the surface of the neural retinal sheet; (9) The area of the continuous epithelial structure is 80% or more of the total area of the apical surface of the neural retina layer, (10) Expression of neural retinal cell-related genes in the neural retinal sheet is observed, and expression of non-neural retinal cell-related genes is not observed, and the non-neural retinal cell-related genes include one or more genes selected from the group consisting of cerebrospinal tissue marker genes and eyeball-related tissue marker genes. Neuroretinal sheet.
[18] The neural retina sheet according to
[17] above, having a major axis of 600 μm to 2500 μm.
[19] The neural retina sheet according to
[17] or
[18] above, having a minor axis of 200 μm to 1500 μm.
[20] The neural retina sheet according to any one of the above
[17] to
[19] , which has a height of 100 μm to 1000 μm. [twenty one] The neural retina sheet is (1) isolated from a cell aggregate containing the neural retina; (2) comprising a region near the center of the continuous epithelial tissue in the cell aggregate; and (3) The major axis is 600 μm to 2500 μm, the minor axis is 200 μm to 1500 μm, and the height is 100 μm to 1000 μm. The neural retina sheet according to any one of
[17] to
[20] above. [twenty two] The neural retina sheet is (1) isolated from a cell aggregate comprising at least a first epithelial tissue and a second epithelial tissue; The cell aggregate comprises: the first epithelial tissue comprising a human neural retina; the second epithelial tissue comprising a surface tangent slope continuity different from the surface tangent slope continuity of the first epithelial tissue; and comprising non-neural retinal cells; (2) including an area of the first epithelium that is furthest from the second epithelium; and (3) The major axis is 600 μm to 2500 μm, the minor axis is 200 μm to 1500 μm, and the height is 100 μm to 1000 μm, The neural retinal sheet according to any one of
[17] to
[21] above, wherein the second epithelial tissue is a tissue selected from the group consisting of eye-related tissues, cerebrospinal tissues, and other tissues different from the neural retina of the first epithelial tissue. [twenty three] The neural retina sheet according to any one of
[17] to
[22] above, wherein the ratio of Rx positive cells to the total number of cells in the neural retina sheet is 30% or more and 80% or less, 40% or more and 70% or less, 45% or more and 60% or less, or 50% or more and 60% or less. [twenty four] The neural retina sheet according to any one of
[17] to
[23] above, wherein the ratio of Chx10 positive cells to the total number of cells in the neural retina sheet is 10% or more and 80% or less, 20% or more and 70% or less, 30% or more and 60% or less, or 40% or more and 50% or less. [twenty five] The neural retina sheet according to any one of
[17] to
[24] above, wherein the ratio of Pax6 positive cells to the total number of cells in the neural retina sheet is 10% or more and 80% or less, 20% or more and 70% or less, 30% or more and 60% or less, or 40% or more and 50% or less.
[26] The neural retina sheet according to any one of
[17] to
[25] above, wherein the ratio of Crx-positive cells to the total number of cells in the neural retina sheet is 10% or more and 70% or less, 10% or more and 60% or less, 20% or more and 60% or less, 30% or more and 60% or less, 40% or more and 60% or less, or 50% or more and 60% or less.
[27] A pharmaceutical composition comprising the neural retina sheet according to any one of
[17] to
[26] above.
[28] A method for treating a disease caused by a disorder of neural retinal cells or the neural retina, or damage to the neural retina, comprising transplanting the neural retina sheet described in any one of
[17] to
[26] above into a subject in need of transplantation.
[29] Using the method according to any one of [1] to
[16] above, a cell aggregate containing a neural retina having an epithelial structure derived from pluripotent stem cells is evaluated, and a neural retina for transplantation that is determined to be usable as a neural retina for transplantation is selected; and Isolating the selected neural retina for transplantation. The method for producing a neural retina sheet according to any one of the above
[17] to
[26] , comprising:
[30] Extracting a quality assessment sample, which is a part of a cell aggregate, from each of 2 to 800 cell aggregates including a neural retina having an epithelial structure derived from pluripotent stem cells; Evaluating the extracted 2 to 800 quality assessment samples by any one of the methods described in [1] to
[16] above, and selecting neural retina for transplantation that is determined to be usable as neural retina for transplantation; and Isolating the selected neural retina for transplantation. A method for producing a neural retinal sheet comprising the steps of:
[31] the cell aggregate is a cell aggregate obtained by inducing differentiation of pluripotent stem cells, and includes at least a first epithelial tissue and a second epithelial tissue, the first epithelial tissue includes a human neural retina, the second epithelial tissue has a continuity of the tangent slope of a surface different from the continuity of the tangent slope of the surface of the first epithelial tissue, and includes non-neural retinal cells; The isolation of the neural retina for transplantation is performed from the cell aggregate such that the neural retina for transplantation includes a region on the first epithelium that is furthest from the second epithelium. The manufacturing method according to
[29] or
[30] above. Effect of the Invention
[0010] According to the present invention, it is possible to provide a method for evaluating the quality of a neural retina for transplantation, a neural retina sheet for transplantation selected by said method, and a method for producing said neural retina sheet for transplantation. [Brief description of the drawings]
[0011] [Figure 1] 1 is a fluorescent microscope image showing the results of immunostaining with Crx and Chx10 on a cell aggregate containing a neural retina for transplantation in Example 1. [Diagram 2]1 shows fluorescence microscopy images showing the results of immunostaining with Rx and Recoverin on a cell aggregate containing a neural retina for transplantation in Example 1. [Diagram 3] 1 shows the results of microarray analysis of RNA extracted from neural retina and by-products A, B, C, D, E and F in Example 2. [Figure 4] FIG. 1 is a schematic diagram of the creation of caps and rings from typical cell aggregates. [Diagram 5] A schematic diagram of the creation of caps and rings from cell aggregates of various shapes. The black and grey areas represent extraneous tissue. [Figure 6] 1 shows the height, major axis, and minor axis of the graft in Example 4, together with an image of a typical graft and a schematic diagram of the graft. [Figure 7] 13 is a confocal fluorescence microscope image showing the results of immunostaining of the graft with Crx and Chx10 in Example 5. [Figure 8] 1 shows the results of quantitative PCR analysis of gene expression in RNA extracted from the cap and ring in Example 6. [Figure 9] 13 shows the results of quantitative PCR analysis of gene expression in RNA extracted from the cap and ring in Example 7. [Figure 10] 13 is an image showing the results of observing the post-transplant engraftment image using a fluorescent microscope after RNA extracted from the ring was analyzed by quantitative PCR and then a graft (cap) was transplanted under the rat retina in Example 8. [Figure 11] 13 is an image showing the results of observing the engraftment after transplantation under a fluorescent microscope in Example 9, in which RNA extracted from the ring was analyzed by quantitative PCR, and then a graft (cap) was transplanted under the rat retina. [Figure 12] 13 shows an image of a ring observed with an inverted microscope in Example 10, and an image showing the engraftment after the ring was transplanted under the retina of a rat and observed with a fluorescence microscope. [Figure 13]11 is a fluorescent microscope image showing the results of immunostaining of a cap and a ring made from a single cell aggregate in Example 11. [Figure 14] 13 shows the results of quantitative PCR analysis of gene expression in RNA extracted from caps and rings prepared from neural retina and non-neural retina (telencephalic tissue, spinal cord tissue, RPE, optic stalk) in Example 12. [Figure 15] 1 shows an immunostained image of a stained section in Example 14 observed using a fluorescence microscope (Keyence). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0012] [Definition] "Stem cells" refer to undifferentiated cells that have differentiation and proliferation capabilities (particularly self-renewal capabilities). Stem cells include subpopulations such as pluripotent stem cells, multipotent stem cells, and unipotent stem cells, depending on their differentiation capabilities. Pluripotent stem cells refer to stem cells that can be cultured in vitro and have the ability (pluripotency) to differentiate into all cell lineages belonging to the three germ layers (ectoderm, mesoderm, and endoderm) and / or extraembryonic tissues. Multipotent stem cells refer to stem cells that have the ability to differentiate into multiple types of tissues and cells, but not all types. Unipotent stem cells refer to stem cells that have the ability to differentiate into specific tissues and cells.
[0013] "Pluripotent stem cells" can be derived from fertilized eggs, cloned embryos, germline stem cells, tissue stem cells, somatic cells, etc. Examples of pluripotent stem cells include embryonic stem cells (ES cells), embryonic germ cells (EG cells), and induced pluripotent stem cells (iPS cells). Muse cells (multi-lineage differentiating stress enduring cells) obtained from mesenchymal stem cells (MSCs) and GS cells produced from germ cells (e.g., testes) are also included in pluripotent stem cells.
[0014] Human embryonic stem cells were established in 1998 and are being used in regenerative medicine. Embryonic stem cells can be produced by culturing inner cell aggregates on feeder cells or in a medium containing bFGF. Methods for producing embryonic stem cells are described in, for example, WO96 / 22362, WO02 / 101057, US5,843,780, US6,200,806, US6,280,718, etc. Embryonic stem cells can be obtained from a designated institution, and can also be purchased commercially. For example, human embryonic stem cells KhES-1, KhES-2, and KhES-3 are available from the Institute for Frontier Medical Sciences, Kyoto University. Human embryonic stem cells Crx::Venus strain (derived from KhES-1) are available from the National Institute of Physical and Chemical Research.
[0015] An "induced pluripotent stem cell" is a cell in which pluripotency has been induced by reprogramming a somatic cell using a known method or the like.
[0016] In 2006, Yamanaka et al. established induced pluripotent stem cells in mouse cells (Cell, 2006, 126(4), pp.663-676). In 2007, induced pluripotent stem cells were also established in human fibroblast cells, and they have the same pluripotency and self-renewal ability as embryonic stem cells (Cell, 2007, 131(5), pp.861-872; Science, 2007, 318(5858), pp.1917-1920; Nat. Biotechnol., 2008, 26(1), pp.101-106).
[0017] Specifically, induced pluripotent stem cells include cells in which pluripotency is induced by reprogramming somatic cells differentiated into fibroblasts or peripheral blood mononuclear cells by expressing any combination of multiple genes selected from a group of reprogramming genes including Oct3 / 4, Sox2, Klf4, Myc (c-Myc, N-Myc, L-Myc), Glis1, Nanog, Sall4, lin28, Esrrb, etc. Preferred combinations of reprogramming factors include (1) Oct3 / 4, Sox2, Klf4, and Myc (c-Myc or L-Myc), and (2) Oct3 / 4, Sox2, Klf4, Lin28, and L-Myc (Stem Cells, 2013;31:458-466).
[0018] In addition to producing induced pluripotent stem cells by direct reprogramming through gene expression, induced pluripotent stem cells can also be induced from somatic cells by adding chemical compounds (Science, 2013, 341, pp. 651-654).
[0019] It is also possible to obtain established induced pluripotent stem cells, and for example, human induced pluripotent cell lines such as 201B7 cells, 201B7-Ff cells, 253G1 cells, 253G4 cells, 1201C1 cells, 1205D1 cells, 1210B2 cells, and 1231A3 cells established at Kyoto University are available from Kyoto University and iPS Academia Japan Inc. As established induced pluripotent stem cells, for example, Ff-I01 cells, Ff-I14 cells, and QHJI01s04 cells established at Kyoto University are available from Kyoto University.
[0020] In this specification, the pluripotent stem cells are preferably embryonic stem cells or induced pluripotent stem cells, and more preferably induced pluripotent stem cells.
[0021] In this specification, pluripotent stem cells are human pluripotent stem cells, preferably human induced pluripotent stem cells (iPS cells) or human embryonic stem cells (ES cells).
[0022] Pluripotent stem cells such as human iPS cells can be subjected to maintenance culture and expansion culture by methods well known to those skilled in the art.
[0023] "Retinal tissue" refers to tissue in which one or more types of retinal cells that make up each retinal layer in a living retina exist according to a certain order, and "neural retina" refers to retinal tissue that includes the inner neural retinal layer, which does not include the retinal pigment epithelium layer, among the retinal layers described below.
[0024] "Retinal cells" refers to cells that constitute each retinal layer in a living retina or their precursor cells. Retinal cells include, but are not limited to, photoreceptors (rod photoreceptors, cone photoreceptors), horizontal cells, amacrine cells, interneurons, retinal ganglion cells (ganglion cells), bipolar cells (rod bipolar cells, cone bipolar cells), Müller glial cells, retinal pigment epithelial (RPE) cells, ciliary bodies, their precursor cells (e.g., photoreceptor precursor cells, bipolar cell precursor cells, etc.), retinal precursor cells, etc. Among retinal cells, cells constituting the neural retinal layer (also called neural retina cells or neural retina-related cells) specifically include photoreceptors (rod photoreceptors, cone photoreceptors), horizontal cells, amacrine cells, interneuronal cells, retinal ganglion cells (ganglion cells), bipolar cells (rod bipolar cells, cone bipolar cells), Muller glial cells, and their precursor cells (e.g., photoreceptor precursor cells, bipolar cell precursor cells, etc.). In other words, neural retinal cells do not include retinal pigment epithelial cells and ciliary body cells.
[0025] "Mature retinal cells" refers to cells that can be contained in the retinal tissue of human adults, specifically, differentiated cells such as photoreceptors (rod photoreceptors, cone photoreceptors), horizontal cells, amacrine cells, interneurons, retinal ganglion cells (ganglion cells), bipolar cells (rod bipolar cells, cone bipolar cells), Muller glial cells, retinal pigment epithelial (RPE) cells, ciliary cells, etc. "Immature retinal cells" refers to precursor cells (e.g., photoreceptor precursor cells, bipolar cell precursor cells, retinal precursor cells, etc.) that are committed to differentiating into mature retinal cells.
[0026] Photoreceptor precursor cells, horizontal cell precursor cells, bipolar cell precursor cells, amacrine cell precursor cells, retinal ganglion cell precursor cells, Müller glial precursor cells, and retinal pigment epithelial precursor cells refer to precursor cells that are committed to differentiating into photoreceptor cells, horizontal cells, bipolar cells, amacrine cells, retinal ganglion cells, Müller glial cells, and retinal pigment epithelial cells, respectively.
[0027] The term "retinal progenitor cells" refers to precursor cells that can differentiate into any immature retinal cell, such as photoreceptor precursor cells, horizontal cell precursor cells, bipolar cell precursor cells, amacrine cell precursor cells, retinal ganglion cell precursor cells, Muller glial cells, and retinal pigment epithelial precursor cells, and ultimately, to precursor cells that can differentiate into any mature retinal cell, such as photoreceptors, rod photoreceptors, cone photoreceptors, horizontal cells, bipolar cells, amacrine cells, retinal ganglion cells, and retinal pigment epithelial cells.
[0028] In living organisms, photoreceptor cells exist in the photoreceptor layer of the retina and have the role of absorbing light stimuli and converting them into electrical signals. There are two types of photoreceptor cells: cones that function in bright light and rods that function in dark light (called cone photoreceptors and rod photoreceptors, respectively). Examples of cone photoreceptor cells include S-cone photoreceptors that express S-opsin and receive blue light, L-cone photoreceptors that express L-opsin and receive red light, and M-cone photoreceptors that express M-opsin and receive green light. Photoreceptor cells differentiate and mature from photoreceptor precursor cells. Those skilled in the art can easily confirm whether a cell is a photoreceptor cell or a photoreceptor precursor cell by, for example, the expression of cell markers described below (Crx and Blimp1 expressed in photoreceptor precursor cells, Recoverin expressed in photoreceptors, rhodopsin, S-Opsin, and M / L-Opsin expressed in mature photoreceptors, etc.), the formation of an outer segment structure, etc. In one embodiment, the photoreceptor precursor cells are Crx-positive cells, and the photoreceptors are rhodopsin, S-Opsin, and M / L-Opsin-positive cells. In one embodiment, the rod photoreceptors are NRL and Rhodopsin-positive cells. In one embodiment, the S cone photoreceptors are S-opsin-positive cells, the L cone photoreceptors are L-opsin-positive cells, and the M cone photoreceptors are M-opsin-positive cells.
[0029] The presence of neural retinal cells can be confirmed by the presence or absence of expression of neural retinal cell-related genes (hereinafter sometimes referred to as "neural retinal cell markers" or "neural retinal markers"). The presence or absence of expression of neural retinal cell markers, or the proportion of neural retinal cell marker-positive cells in a cell population or tissue, can be easily confirmed by those skilled in the art. For example, a method using an antibody, a method using a nucleic acid primer, and a method using a sequence reaction can be mentioned. As a method using an antibody, the expression of a protein of a neural retinal cell marker can be confirmed by dividing the number of cells positive for a specific neural retinal cell marker by the total number of cells, for example, by a method such as flow cytometry or immunostaining using a commercially available antibody. As a method using a nucleic acid primer, the expression of RNA of a neural retinal cell marker can be confirmed, for example, by PCR, semi-quantitative PCR, or quantitative PCR (e.g., real-time PCR). As a method using a sequence reaction, the expression of RNA of a neural retinal cell marker can be confirmed, for example, by using a nucleic acid sequencer (e.g., next-generation sequencer).
[0030] Examples of neural retinal cell markers include Rx (also called Rax) and PAX6 expressed in retinal progenitor cells, Rx, PAX6 and Chx10 (also called Vsx2) expressed in neural retinal progenitor cells, and Crx and Blimp1 expressed in photoreceptor progenitor cells. Other examples include Chx10, which is strongly expressed in bipolar cells; PKCα, Goα, VSX1, and L7, which are expressed in bipolar cells; TuJ1 and Brn3, which are expressed in retinal ganglion cells; Calretinin and HPC-1, which are expressed in amacrine cells; Calbindin, which is expressed in horizontal cells; Recoverin, which is expressed in photoreceptor cells and photoreceptor precursor cells; Rhodopsin, which is expressed in rod cells; Nrl, which is expressed in rod photoreceptor cells and rod photoreceptor precursor cells; S-opsin and LM-opsin, which are expressed in cone photoreceptor cells; RXR-γ, which is expressed in cone cells, cone photoreceptor precursor cells, and ganglion cells; TRβ2, OTX2, and OC2, which are expressed in cone photoreceptor cells or their precursor cells that appear in the early differentiation stage of cone photoreceptor cells; and Pax6, which is expressed in horizontal cells, amacrine cells, and ganglion cells.
[0031] "Positive cell" refers to a cell that expresses a particular marker on the cell surface or intracellularly. For example, "Chx10 positive cell" refers to a cell that expresses Chx10 protein.
[0032] "Retinal pigment epithelial cells" refers to epithelial cells present outside the neural retina in a living retina. Those skilled in the art can easily confirm whether a cell is a retinal pigment epithelial cell by, for example, the expression of cell markers (RPE65, MITF, CRALBP, MERTK, BEST1, TTR, etc.), the presence of melanin granules (black-brown color), tight junctions between cells, characteristic polygonal and paving-stone cellular morphology, etc. Whether a cell has the function of a retinal pigment epithelial cell can be easily confirmed by the secretion ability of cytokines such as VEGF and PEDF, etc. In one embodiment, the retinal pigment epithelial cell is an RPE65-positive cell, an MITF-positive cell, or an RPE65-positive and MITF-positive cell.
[0033] "Retinal layer" means each layer that constitutes the retina, and specific examples include the retinal pigment epithelium layer, photoreceptor layer, outer limiting membrane, outer nuclear layer, outer plexiform layer, inner nuclear layer, inner plexiform layer, ganglion cell layer, nerve fiber layer, and inner limiting membrane.
[0034] "Neural retinal layer" refers to each layer constituting the neural retina, and specifically includes the photoreceptor layer, the outer limiting membrane, the outer nuclear layer, the outer plexiform layer, the inner nuclear layer, the inner plexiform layer, the ganglion cell layer, the nerve fiber layer, and the inner limiting membrane. "Photoreceptor layer" refers to the retinal layer formed on the outermost side of the neural retina and containing many photoreceptors (rod photoreceptors, cone photoreceptors), photoreceptor precursor cells, and retinal precursor cells. Each layer other than the photoreceptor layer is called an inner layer. It can be confirmed which retinal layer each cell constitutes by a known method, for example, the presence or absence of expression or the degree of expression of a cell marker.
[0035] In the case of retinal tissue at a stage where the appearance ratio of photoreceptor cells or photoreceptor precursor cells is low, the layer containing the proliferating neural retinal precursor cells is called the "neuroblastic layer", and there are an inner neuroblastic layer and an outer neuroblastic layer. Those skilled in the art can distinguish the layer by well-known methods, for example, by the color shading (the outer neuroblastic layer is light and the inner neuroblastic layer is dark) under a bright field microscope.
[0036] The term "ciliary body" includes the "ciliary body" during development and in adults, the "ciliary margin" and the "ciliary body". Markers of the "ciliary body" include Zic1, MAL, HNF1beta, FoxQ1, CLDN2, CLDN1, GPR177, AQP1 and AQP4. The "ciliary marginal zone (CMZ)" can be, for example, a tissue that exists in the boundary region between the neural retina and the retinal pigment epithelium in a living retina, and can include a region that contains retinal tissue stem cells (retinal stem cells). The ciliary margin is also called the ciliary margin or retinal margin, and the ciliary margin, ciliary margin and retinal margin are equivalent tissues. The ciliary margin is known to play an important role in supplying retinal progenitor cells and differentiated cells to retinal tissue, maintaining retinal tissue structure, and the like. Examples of marker genes for the ciliary margin include the Rdh10 gene (positive), the Otx1 gene (positive), and the Zic1 gene (positive). The term "ciliary margin-like structure" refers to a structure similar to the ciliary margin.
[0037] The term "cell aggregate" is not particularly limited as long as a plurality of cells are adhered to each other to form a three-dimensional structure, and refers to, for example, a mass formed by the assembly of cells dispersed in a medium such as a culture medium, or a mass of cells formed through cell division. Cell aggregates also include those that form a specific tissue.
[0038] The term "sphere-shaped cell aggregate" refers to a cell aggregate having a three-dimensional shape close to a sphere. The three-dimensional shape close to a sphere is a shape having a three-dimensional structure, and examples of such shapes include a spherical shape that shows a circular or elliptical shape when projected onto a two-dimensional surface, and a shape formed by the fusion of multiple spherical shapes (for example, a shape formed by two to four overlapping circular or elliptical shapes when projected onto a two-dimensional surface). In one embodiment, the core of the aggregate has a vesicular layered structure, and is characterized in that the center is dark and the outer edge is bright under a bright-field microscope.
[0039] In one embodiment, epithelial tissue is polarized to form an "apical surface" and a "basement membrane." The term "basement membrane" refers to a basement membrane in which a basal layer (basement membrane) of 50-100 nm produced by epithelial cells containing a large amount of laminin and type IV collagen is present. The term "apical surface" refers to a surface (superficial surface) formed on the opposite side of the "basement membrane." In one embodiment, the term "apical surface" refers to a surface in contact with the photoreceptor layer (external nuclear layer) in which the outer limiting membrane is formed and the photoreceptor and photoreceptor precursor cells are present in retinal tissue whose developmental stage has progressed to the extent that photoreceptor cells or photoreceptor precursor cells can be found. In addition, such an apical surface can be identified by immunostaining methods well known to those skilled in the art using antibodies against apical surface markers (e.g., atypical-PKC (hereinafter abbreviated as "aPKC"), E-cadherin, and N-cadherin).
[0040] "Epithelial tissue" refers to tissue formed by cells tightly covering the surface of the body, lumen (such as the digestive tract), and body cavity (such as the pericardial cavity). Cells forming epithelial tissue are called epithelial cells. Epithelial cells have apical-basal polarity. Epithelial cells can form a layer of cells by forming strong bonds between epithelial cells through adherens junctions and / or tight junctions. Epithelial tissue is a tissue formed by stacking one to a dozen or so cell layers. Tissues that can form epithelial tissue include fetal and / or adult retinal tissue, cerebrospinal tissue, ocular tissue, and nervous tissue. The neural retina in this specification is also epithelial tissue. "Epithelial structure" refers to a structure that epithelial tissue has characteristically, such as an apical surface or a basement membrane.
[0041] "Continuous epithelial tissue" refers to tissue having a continuous epithelial structure. A continuous epithelial structure refers to a state in which epithelial tissue is continuous. For example, continuous epithelial tissue refers to a state in which 10 cells to 10 cells are connected in a tangential direction to the epithelial tissue. 7 cells, preferably 30 cells to 10 cells in the tangential direction 7 cells, more preferably 10 2 cells ~10 7 It refers to cells arranged in a row.
[0042] For example, the continuous epithelial structure formed in the retinal tissue has an apical surface characteristic of epithelial tissue, and the apical surface is formed on the surface of the retinal tissue generally parallel to and continuous with at least the photoreceptor layer (outer nuclear layer) among the layers forming the neural retina. For example, in the case of a cell aggregate containing retinal tissue produced from pluripotent stem cells, the apical surface is formed on the surface of the aggregate, and 10 or more, preferably 30 or more, more preferably 100 or more, and even more preferably 400 or more photoreceptor cells or photoreceptor precursor cells are regularly and continuously arranged in the tangential direction to the surface.
[0043] [Method for evaluating the quality of neural retina for transplantation] One aspect of the invention is a method for assessing the quality of a neural retina for transplantation.
[0044] The method of the present invention includes extracting a part or all of a cell aggregate including a neural retina having an epithelial structure derived from pluripotent stem cells as a quality assessment sample, detecting the expression of neural retinal cell (target cell)-related genes and non-neural retinal cell (non-target cell)-related genes in the quality assessment sample, and, when expression of neural retinal cell-related genes (target cell-related genes) is observed and expression of non-neural retinal cell-related genes (non-target cell-related genes) is not observed, determining that (1) the neural retina (neural retina for transplantation) in the same cell aggregate as the cell aggregate including the quality assessment sample, which is a part of the cell aggregate, (2) the neural retina (neural retina for transplantation) in a cell aggregate of the same lot as the cell aggregate including the quality assessment sample, which is a part of the cell aggregate, or (3) the neural retina (neural retina for transplantation) in a cell aggregate of the same lot as the cell aggregate of the quality assessment sample, which is the whole of the cell aggregate, is usable as a neural retina for transplantation. If expression of neural retinal cell-related genes (target cell-related genes) is observed in the quality assessment sample, and expression of non-neural retinal cell-related genes (non-target cell-related genes) is not observed, the quality assessment sample is determined to be usable as a neural retina for transplantation; however, since the quality assessment sample, which is the neural retina for transplantation, is destroyed for evaluation, it cannot actually be used for transplantation.
[0045] <Cell aggregates including the neural retina> (Method for producing cell aggregates) The cell aggregates including neural retina in this specification have an epithelial structure and can be obtained by inducing differentiation of pluripotent stem cells. One embodiment includes a method for producing cell aggregates including neural retina using a differentiation inducer. Examples of the differentiation inducer include a basement membrane preparation, a substance acting on the BMP signaling pathway, a substance inhibiting the Wnt signaling pathway, and a substance acting on the IGF signaling pathway. One embodiment includes a method for producing cell aggregates including neural retina by self-organization. Self-organization refers to a mechanism by which a group of cells autonomously produces a complex structure. For example, self-organization can be performed by the SFEB (Serum-free Floatingculture of Embryoid Bodies-like aggregates) method (WO2005 / 12390) or the SFEBq method (WO2009 / 148170).
[0046] Specific examples of differentiation induction methods include, but are not limited to, those disclosed in WO2011 / 055855, WO2013 / 077425, WO2015 / 025967, WO2016 / 063985, WO2016 / 063986, WO2017 / 183732, PLoS One. 2010 Jan 20;5(1):e8763., Stem Cells. 2011 Aug;29(8):1206-18., Proc Natl Acad Sci USA. 2014 Jun 10;111(23):8518-23, or Nat Commun. 2014 Jun 10;5:4047.
[0047] In one specific embodiment, a cell aggregate containing a neural retina can be prepared by a method including the following steps (A), (B) and (C). (A) culturing pluripotent stem cells in a medium containing an undifferentiated maintenance factor in the absence of feeder cells; (B) forming cell aggregates by suspension culture of the cells obtained in step (A); (C) A step of further culturing the cell aggregates obtained in step (B) in a suspension culture medium containing a substance acting on a BMP signaling pathway. In addition, step (A) may further include a TGFβ family signaling pathway inhibitor and / or a Sonic Hedgehog signaling pathway agonist. Furthermore, step (B) may include a substance that acts on the Sonic Hedgehog signaling pathway and / or a substance that inhibits Wnt signaling, as described below.
[0048] This method is also disclosed in, for example, WO2015 / 025967, WO2016 / 063985, and WO2017 / 183732, and more detailed information can be found in WO2015 / 025967, WO2016 / 063985, and WO2017 / 183732.
[0049] The medium used for preparing the cell aggregates containing the neural retina can be a basal medium for cell proliferation (also called basal medium) unless otherwise specified. The basal medium for cell proliferation is not particularly limited as long as it can culture cells, and a basal medium that is commercially available as a medium for cell proliferation can be used as appropriate. Specifically, for example, BME medium, BGJb medium, CMRL 1066 medium, Glasgow MEM (GMEM) medium, Improved MEM Zinc Option medium, IMDM medium, Medium 199 medium, MEM medium, Eagle MEM medium, αMEM medium, DMEM medium, F-12 medium, DMEM / F12 medium, IMDM / F12 medium, Ham's medium, RPMI 1640 medium, Fischer's medium, Leibovitz's L-15 medium, or a mixture of these mediums, which can be used for culturing animal cells, can be mentioned. In addition, a medium supplemented with N2 medium, which is a supplementary medium, may be used.
[0050] The TGFβ family signaling pathway inhibitor refers to a substance that inhibits the TGFβ family signaling pathway, i.e., a signaling pathway transmitted by the Smad family, and specifically includes TGFβ signaling pathway inhibitors (e.g., SB431542, LY-364947, SB505124, A-83-01, etc.), Nodal / Activin signaling pathway inhibitors (e.g., SB431542, A-83-01, etc.), and BMP signaling pathway inhibitors (e.g., LDN193189, Dorsomorphin, etc.). These substances are commercially available.
[0051] Sonic hedgehog (hereinafter sometimes referred to as "Shh") signaling pathway agonists are substances that can enhance signal transduction mediated by Shh. Examples of Shh signaling pathway agonists include SHH, partial peptides of SHH, PMA (purmorphamine), SAG (smoothened agonist), etc.
[0052] The concentrations of the TGFβ family signaling pathway inhibitor and the Sonic Hedgehog signaling pathway activator may be any concentration capable of inducing differentiation into retinal cells. For example, SB431542 is usually used at a concentration of 0.1 to 200 μM, preferably 2 to 50 μM. A-83-01 is usually used at a concentration of 0.05 to 50 μM, preferably 0.5 to 5 μM. LDN193189 is usually used at a concentration of 1 to 2000 nM, preferably 10 to 300 nM. SAG is usually used at a concentration of 1 to 2000 nM, preferably 10 to 700 nM. PMA is usually used at a concentration of 0.002 to 20 μM, preferably 0.02 to 2 μM.
[0053] The undifferentiated state maintaining factor is not particularly limited as long as it is a substance that has an effect of suppressing the differentiation of pluripotent stem cells. Examples of undifferentiated state maintaining factors commonly used by those skilled in the art include substances acting on the FGF signaling pathway, substances acting on the TGFβ family signaling pathway, insulin, and the like. Specific examples of substances acting on the FGF signaling pathway include fibroblast growth factors (e.g., bFGF, FGF4, and FGF8). Furthermore, examples of substances acting on the TGFβ family signaling pathway include substances acting on the TGFβ signaling pathway and substances acting on the Nodal / Activin signaling pathway. Examples of substances acting on the TGFβ signaling pathway include TGFβ1 and TGFβ2. Examples of substances acting on the Nodal / Activin signaling pathway include Nodal, ActivinA, and ActivinB. When culturing human pluripotent stem cells (human ES cells, human iPS cells), the medium in the first step preferably contains bFGF as an undifferentiated state maintaining factor.
[0054] The concentration of the undifferentiation maintenance factor in the medium used in the first step is a concentration that can maintain the undifferentiated state of the pluripotent stem cells to be cultured, and can be appropriately set by a person skilled in the art. For example, specifically, when bFGF is used as the undifferentiation maintenance factor in the absence of feeder cells, the concentration is usually about 4 ng to 500 ng / mL, preferably about 10 ng to 200 ng / mL, more preferably about 30 ng to 150 ng / mL.
[0055] Many synthetic media containing factors for maintaining undifferentiation have been developed and are commercially available as feeder-free media that can be used to culture pluripotent stem cells, such as Essential 8 medium (Life Technologies). Essential 8 medium contains L-ascorbic acid-2-phosphate magnesium (64 mg / L), sodium selenium (14 μg / L), insulin (19.4 mg / L), NaHCO3 (543 mg / L), transferrin (10.7 mg / L), bFGF (100 ng / mL), and TGFβ family signaling pathway active substances (TGFβ1 (2 ng / mL) or Nodal (100 ng / mL)) as additives to DMEM / F12 medium (Nature Methods, 8, 424-429 (2011)). Other commercially available feeder-free media include S-medium (DS Pharma Biomedical), StemPro (Life Technologies), hESF9 (Proc. Natl. Acad. Sci. USA. 2008 Sep 9;105(36):13409-14), mTeSR1 (STEMCELL Technologies), mTeSR2 (STEMCELL Technologies), TeSR-E8 (STEMCELL Technologies), or StemFit (Ajinomoto). By using these in the first step, the present invention can be easily carried out. By using these media, it is possible to culture pluripotent stem cells under feeder-free conditions. The medium used in step (A) is, for example, a serum-free medium to which none of the BMP signaling pathway active substances, Wnt signaling pathway active substances, and Wnt signaling pathway inhibitors is added.
[0056] In the culture of pluripotent stem cells under feeder-free conditions in step (A), a suitable matrix may be used as a scaffold to provide the pluripotent stem cells with a scaffold instead of feeder cells. Examples of matrices that can be used as a scaffold include laminin (Nat Biotechnol 28, 611-615, (2010)), laminin fragments (Nat Commun 3, 1236, (2012)), basement membrane preparations (Nat Biotechnol 19, 971-974, (2001)), gelatin, collagen, heparan sulfate proteoglycan, entactin, and vitronectin.
[0057] The culture time of the pluripotent stem cells in step (A) is not particularly limited as long as it is within a range in which the effect of improving the quality of the cell aggregates formed in step (B) can be achieved when the pluripotent stem cells are cultured in the presence of a TGFβ family signaling pathway inhibitor and / or a Sonic hedgehog signaling pathway agonist (e.g., 100 nM to 700 nM), but is usually 0.5 to 144 hours. In one aspect, the culture time is preferably 2 to 96 hours, more preferably 6 to 48 hours, even more preferably 12 to 48 hours, and even more preferably 18 to 28 hours (e.g., 24 hours).
[0058] The medium used in step (B) may be a serum-containing medium or a serum-free medium. From the viewpoint of avoiding contamination with chemically undefined components, a serum-free medium is preferably used. To avoid the complication of preparation, for example, a serum-free medium to which an appropriate amount of a serum substitute such as commercially available KSR has been added may be mentioned. The amount of KSR added to the serum-free medium is usually about 1% to about 30%, preferably about 2% to about 20%.
[0059] In forming aggregates, first, dispersed cells are prepared by dispersing the cells obtained in step (A). The "dispersed cells" obtained by the dispersion operation are, for example, in a state where 70% (preferably 80% or more) or more are single cells and 30% or less (preferably 20% or less) are clumps of 2 to 50 cells. Dispersed cells are in a state where there is almost no adhesion (for example, surface adhesion) between cells.
[0060] A suspension of dispersed cells is seeded in a culture vessel, and the dispersed cells are cultured under non-adhesive conditions to the culture vessel, causing a plurality of cells to gather and form aggregates. In one embodiment, a certain number of dispersed stem cells are placed in each well of a multi-well plate (U-bottom, V-bottom) such as a 96-well plate, and when this is subjected to static culture, the cells rapidly aggregate to form one aggregate in each well (SFEBq method). When cells are cultured in suspension using a 96-well plate, approximately 1 x 10 cells are cultured per well. 3 From about 1×10 5 Cells (preferably about 3 × 10 3 From about 5 × 10 4 cells, approximately 4 x 10 3 From about 2 × 10 4 A solution prepared to form aggregates (cells) is added to the wells, and the plate is left to stand to form aggregates.
[0061] In one embodiment, the medium used in step (B) comprises a Sonic Hedgehog signaling pathway agent. That is, in one specific embodiment, a cell aggregate containing a neural retina can be prepared by a method including the following steps (A), (B), and (C): (A) culturing pluripotent stem cells in a medium containing an undifferentiated maintenance factor, in the absence of feeder cells, and optionally containing a TGFβ family signaling pathway inhibitor and / or a Sonic Hedgehog signaling pathway agonist; (B) forming cell aggregates by culturing the cells obtained in step (A) in suspension in a medium containing a sonic hedgehog signaling pathway active substance; (C) A step of further culturing the cell aggregates obtained in step (B) in a suspension culture medium containing a substance acting on a BMP signaling pathway. The Sonic Hedgehog signaling pathway active substance in step (B) may be any of those described above at the above-mentioned concentrations (e.g., 10 nM to 300 nM). The Sonic Hedgehog signaling pathway active substance is preferably contained in the medium from the start of the suspension culture. A ROCK inhibitor (e.g., Y-27632) may be added to the medium. The culture time is, for example, 12 hours to 6 days. In one example, the medium used in step (B) is a medium to which one or more (preferably all) selected from the group consisting of a BMP signaling pathway active substance, a Wnt signaling pathway active substance, a TGFβ family signaling pathway inhibitor, and a TGFβ family signaling pathway active substance are not added.
[0062] The BMP signaling pathway active substance is a substance that can enhance the signaling pathway mediated by BMP. Examples of the BMP signaling pathway active substance include BMP proteins such as BMP2, BMP4, and BMP7, GDF proteins such as GDF7, anti-BMP receptor antibodies, and BMP partial peptides. BMP2 protein, BMP4 protein, and BMP7 protein are available from, for example, R&D Systems, and GDF7 protein is available from, for example, Wako Pure Chemical Industries.
[0063] The medium used in step (C) may be, for example, a serum-free medium or a serum medium (preferably a serum-free medium) to which a substance acting on the BMP signaling pathway is added. The serum-free medium and the serum medium can be prepared as described above. In one example, the medium used in step (C) is a medium to which one or more (preferably all) selected from the group consisting of a substance acting on the Wnt signaling pathway, a substance inhibiting the TGFβ family signaling pathway, and a substance acting on the TGFβ family signaling pathway is not added. In one example, the medium used in step (C) is a medium to which a substance acting on the Sonic Hedgehog signaling pathway is not added. In addition, the medium used in step (C) may be a medium to which a substance acting on the Wnt signaling pathway is added.
[0064] The concentration of the substance acting on the BMP signaling pathway may be any concentration capable of inducing differentiation into retinal cells. For example, in the case of human BMP4 protein, it is added to the medium at a concentration of about 0.01 nM to about 1 μM, preferably about 0.1 nM to about 100 nM, more preferably about 1 nM to about 10 nM, and even more preferably about 1.5 nM (55 ng / mL).
[0065] The substance acting on the BMP signaling pathway may be added to the medium at least about 24 hours after the start of the suspension culture in step (A), and may be added to the medium within several days (for example, within 15 days) after the start of the suspension culture. Preferably, the substance acting on the BMP signaling pathway is added to the medium between the 1st and 15th days, more preferably between the 1st and 9th days, and most preferably on the 3rd day after the start of the suspension culture.
[0066] In a specific embodiment, for example, on the 1st to 9th day, preferably the 1st to 3rd day, after the start of the suspension culture in step (B), a part or all of the medium is replaced with a medium containing BMP4, the final concentration of BMP4 is adjusted to about 1 to 10 nM, and the cells are cultured in the presence of BMP4 for, for example, 1 to 12 days, preferably 2 to 9 days, and more preferably 2 to 5 days. Here, in order to maintain the same concentration of BMP4, a part or all of the medium can be replaced with a medium containing BMP4 once or twice. Alternatively, the concentration of BMP4 can be reduced stepwise. For example, the concentration of the substance acting on the BMP signaling pathway (BMP4) may be maintained from the 2nd to 10th day after the start of the suspension culture in step (B), and then the concentration of the substance acting on the BMP signaling pathway (BMP4) may be reduced stepwise from the 6th to 20th day after the start of the suspension culture in step (B).
[0067] The culture conditions such as the culture temperature and CO2 concentration in the above steps (A) to (C) can be appropriately set. The culture temperature is, for example, about 30° C. to about 40° C., and preferably about 37° C. The CO2 concentration is, for example, about 1% to about 10%, and preferably about 5%.
[0068] By varying the culture period in the above step (C), retinal cells at various stages of differentiation can be produced as retinal cells contained in the cell aggregate. That is, retinal cells in the cell aggregate containing immature retinal cells (e.g., retinal progenitor cells, photoreceptor progenitor cells) and mature retinal cells (e.g., photoreceptors) at various ratios can be produced. By extending the culture period in step (C), the ratio of mature retinal cells can be increased.
[0069] The above step (B) and / or step (C) may be performed using the method disclosed in WO2017 / 183732. That is, in step (B) and / or step (C), the cells may be cultured in suspension in a medium further containing a Wnt signaling pathway inhibitor to form cell aggregates.
[0070] The Wnt signaling pathway inhibitor used in step (B) and / or step (C) is not particularly limited as long as it can suppress signaling mediated by Wnt, and may be any of a protein, a nucleic acid, a low molecular weight compound, etc. The signal mediated by Wnt is transmitted via a Wnt receptor that exists as a heterodimer of Frizzled (Fz) and LRP5 / 6 (low-density lipoprotein receptor-related protein 5 / 6). Examples of Wnt signaling pathway inhibitors include substances that act directly on Wnt or Wnt receptors (anti-Wnt neutralizing antibodies, anti-Wnt receptor neutralizing antibodies, etc.), substances that suppress the expression of genes encoding Wnt or Wnt receptors (e.g., antisense oligonucleotides, siRNAs, etc.), substances that inhibit the binding of Wnt receptors to Wnt (soluble Wnt receptors, dominant negative Wnt receptors, Wnt antagonists, Dkk1, Cerberus proteins, etc.), substances that inhibit physiological activities resulting from signaling by Wnt receptors [CKI-7 (N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide), D4476 (4-[4-(2 ,3-dihydro-1,4-benzodioxin-6-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide), IWR-1-endo(IWR1e)(4-[(3aR,4S,7R,7aS)-1,3,3a,4,7,7a-hexahydro-1,3-dioxo-4,7-methano-2H-isoindol-2-yl]-N-8-quinolinyl-benzamide), and IWP-2 (N-(6-methyl-2-benzothiazolyl)-2-[(3,4,6,7-tetrahydro-4-oxo-3-phenylthieno[3,2-d]pyrimidin-2-yl)thio]acetamide) and other low molecular weight compounds, etc., but are not limited thereto. The Wnt signaling pathway inhibitor may contain one or more of these. CKI-7, D4476, IWR-1-endo (IWR1e), IWP-2, etc. are known Wnt signaling pathway inhibitors, and are appropriately available as commercial products, etc. IWR1e is preferably used as the Wnt signaling pathway inhibitor.
[0071] The concentration of the Wnt signaling pathway inhibitor in step (B) may be any concentration capable of inducing the formation of favorable cell aggregates. For example, in the case of IWR-1-endo, it is added to the medium at a concentration of about 0.1 μM to about 100 μM, preferably about 0.3 μM to about 30 μM, more preferably about 1 μM to about 10 μM, and even more preferably about 3 μM. When a Wnt signaling pathway inhibitor other than IWR-1-endo is used, it is desirable to use it at a concentration that exhibits the same Wnt signaling pathway inhibitory activity as the above-mentioned IWR-1-endo concentration.
[0072] In step (B), the timing of adding the Wnt signaling pathway inhibitor to the medium is preferably early. The Wnt signaling pathway inhibitor is added to the medium usually within 6 days, preferably within 3 days, more preferably within 1 day, more preferably within 12 hours, and even more preferably at the start of the suspension culture in step (B). Specifically, for example, a basal medium containing a Wnt signaling pathway inhibitor may be added, or a part or whole of the basal medium may be replaced. The period during which the cells obtained in step (A) are allowed to act on the Wnt signaling pathway inhibitor in step (B) is not particularly limited, but preferably, the cells are allowed to act on the Wnt signaling pathway inhibitor after being added to the medium at the start of the suspension culture in step (B) until the end of step (B) (immediately before the addition of the substance acting on the BMP signaling pathway). More preferably, the cells are continuously exposed to the Wnt signaling pathway inhibitor even after the end of step (B) (i.e., during step (C)), as described below. In one embodiment, as described below, the Wnt signaling pathway inhibitor may be allowed to continue to act even after completion of step (B) (i.e., during the period of step (C)) until retinal tissue is formed.
[0073] In step (C), any of the above-mentioned Wnt signaling pathway inhibitors can be used as the Wnt signaling pathway inhibitor. Preferably, the same type of Wnt signaling pathway inhibitor used in step (B) is used in step (C).
[0074] The concentration of the Wnt signaling pathway inhibitor in step (C) may be any concentration capable of inducing retinal progenitor cells and retinal tissue. For example, in the case of IWR-1-endo, it is added to the medium to a concentration of about 0.1 μM to about 100 μM, preferably about 0.3 μM to about 30 μM, more preferably about 1 μM to about 10 μM, and even more preferably about 3 μM. When a Wnt signaling pathway inhibitor other than IWR-1-endo is used, it is desirable to use it at a concentration that exhibits the same Wnt signaling pathway inhibitory activity as the above-mentioned IWR-1-endo concentration. The concentration of the Wnt signaling pathway inhibitor in the medium in step (C) is preferably 50 to 150, more preferably 80 to 120, and even more preferably 90 to 110, when the concentration of the Wnt signaling pathway inhibitor in the medium in step (B) is taken as 100, and it is more preferable that it is the same as the concentration of the Wnt signaling pathway inhibitor in the medium in the second step.
[0075] The timing of adding the Wnt signaling pathway inhibitor to the medium is not particularly limited as long as it can achieve the formation of aggregates containing retinal cells or retinal tissue, but the earlier the better. Preferably, the Wnt signaling pathway inhibitor is added to the medium at the start of step (C). More preferably, after the Wnt signaling pathway inhibitor is added in step (B), it continues to be contained in the medium in step (C) (i.e., from the start of step (B)). Even more preferably, after the Wnt signaling pathway inhibitor is added at the start of the suspension culture in step (B), it continues to be contained in the medium in step (C). For example, a BMP signaling agent (e.g., BMP4) may be added to the culture obtained in step (B) (a suspension of aggregates in a medium containing a Wnt signaling pathway inhibitor).
[0076] The period during which the Wnt signaling pathway inhibitor is allowed to act is not particularly limited, but is preferably 2 to 30 days, more preferably 6 to 20 days, 8 to 18 days, 10 to 18 days, or 10 to 17 days (e.g., 10 days) from the start of suspension culture in step (B) when the Wnt signaling pathway inhibitor is added at the start of suspension culture in step (B). In another embodiment, the period during which the Wnt signaling pathway inhibitor is allowed to act is preferably 3 to 15 days (e.g., 5 days, 6 days, or 7 days), more preferably 6 to 10 days (e.g., 6 days) from the start of suspension culture in step (B) when the Wnt signaling pathway inhibitor is added at the start of suspension culture in step (B).
[0077] The cell aggregates obtained by the above-mentioned method can be cultured in a serum-free medium or serum medium containing a substance acting on the Wnt signaling pathway and / or a substance inhibiting the FGF signaling pathway for about 2 to 4 days (step (D)), and then cultured in a serum-free medium or serum medium not containing a substance acting on the Wnt signaling pathway and a substance inhibiting the FGF signaling pathway for about 30 to 200 days (30 to 150 days, 50 to 120 days, 60 to 90 days) (step (E)), thereby producing a neural retina containing a ciliary margin-like structure.
[0078] In one embodiment, a neural retina containing a ciliary margin-like structure can be produced from the cell aggregates obtained in steps (A) to (C), which are on the 6th to 30th day, 10th to 20th day (the 10th, 11th, 12th, 13th, 14th, 15th, 16th, 17th, 18th, 19th or 20th day) after the start of suspension culture in step (B), by the above steps (D) and (E).
[0079] The substance acting on the Wnt signaling pathway is not particularly limited as long as it can enhance the signal transduction mediated by Wnt. Specific examples of the substance acting on the Wnt signaling pathway include GSK3β inhibitors (e.g., 6-Bromoindirubin-3'-oxime (BIO), CHIR99021, and Kenpaullone). For example, in the case of CHIR99021, the range can be about 0.1 μM to about 100 μM, preferably about 1 μM to about 30 μM.
[0080] The FGF signaling pathway inhibitor is not particularly limited as long as it can inhibit the signal transduction mediated by FGF. Examples of the FGF signaling pathway inhibitor include SU-5402, AZD4547, BGJ398, etc. For example, in the case of SU-5402, it is added at a concentration of about 0.1 μM to about 100 μM, preferably about 1 μM to about 30 μM, more preferably about 5 μM.
[0081] In one example, the medium used in step (D) is a medium to which one or more (preferably all) selected from the group consisting of a BMP signaling pathway active substance, a Wnt signaling pathway inhibitor, an SHH signaling pathway active substance, a TGFβ family signaling pathway inhibitor, and a TGFβ family signaling pathway active substance are not added.
[0082] A part or all of the steps of the above step (E) can be cultured using the continuous epithelial tissue maintenance medium disclosed in WO2019 / 017492. That is, by culturing using a continuous epithelial tissue maintenance medium, the continuous epithelial structure of the neural retina can be maintained. As an example, a medium obtained by compounding B27 supplement (e.g., Thermo Fisher Scientific, 12587010) with Neurobasal medium (e.g., Thermo Fisher Scientific, 21103049) can be cited as a continuous epithelial tissue maintenance medium.
[0083] In the culture in step (E) above, in order to achieve both differentiation and / or maturation of retinal cells (particularly photoreceptor cells) and maintenance of a continuous epithelial structure, it is preferable to gradually replace the medium with a medium for maintaining continuous epithelial tissue. For example, the cells can be cultured in a basal cell proliferation medium (e.g., a medium in which 10% fetal bovine serum, 1% N2 supplement, and 100 μM taurine are added to DMEM / F12 medium) for the first 10 to 30 days, in a mixed medium of a basal cell proliferation medium and a medium for continuous epithelial tissue maintenance (a medium in which a medium in which 10% fetal bovine serum, 1% N2 supplement, and 100 μM taurine is added to DMEM / F12 medium and a medium in which 10% fetal bovine serum, 2% B27 supplement, 2 mM glutamine, and 100 μM taurine are added to Neurobasal medium at a ratio of 1:3) for the next 10 to 40 days, and in a continuous epithelial tissue maintenance medium (e.g., a medium in which 10% fetal bovine serum, 2% B27 supplement, 2 mM glutamine, and 100 μM taurine are added to Neurobasal medium) for the next 20 to 140 days.
[0084] In some or all of the steps of the above step (E), whether a basal cell proliferation medium, a continuous epithelial tissue maintenance medium, or a mixed medium thereof is used, the medium may further contain a substance acting on the thyroid hormone signaling pathway. By culturing in a medium containing a substance acting on the thyroid hormone signaling pathway, it becomes possible to produce a cell aggregate containing a neural retina in which the proportion of bipolar cells, amacrine cells, ganglion cells, horizontal cells, etc. contained in the neural retina is low and the proportion of photoreceptor precursor cells is increased.
[0085] In this specification, a substance acting on the thyroid hormone signaling pathway is a substance capable of enhancing signal transduction mediated by thyroid hormone, and is not particularly limited as long as it can enhance the thyroid hormone signaling pathway. Examples of substances acting on the thyroid hormone signaling pathway include triiodothyronine (hereinafter sometimes abbreviated as T3), thyroxine (hereinafter sometimes abbreviated as T4), thyroid hormone receptor (preferably TRβ receptor) agonists, etc.
[0086] Further, examples of thyroid hormone receptor agonists known to those skilled in the art include those described in WO 97 / 21993, WO 2004 / 066929, WO 2004 / 093799, WO 2000 / 039077, WO 2001 / 098256, WO 2003 / 018515, WO 2003 / 084915, WO 2002 / 094319, WO 2003 / 064369, JP 2003-20066929, and the like. Examples of the diphenylmethane derivatives include compounds such as diphenylmethane derivatives, diaryl ether derivatives, pyridazine derivatives, pyridine derivatives, and indole derivatives described in JP02-053564A, JP2002-370978A, JP2000-256190A, WO2007 / 132475A, WO2007 / 009913A, WO2003 / 094845A, WO2002 / 051805A, and WO2010 / 122980A.
[0087] When T3 is used as the substance acting on the thyroid hormone signaling pathway, it can be added to the medium in a range of, for example, 0.1 to 1000 nM. Preferably, the concentration is 1 to 500 nM; more preferably, 10 to 100 nM; even more preferably, 30 to 90 nM; and even more preferably, the concentration has a thyroid hormone signaling enhancing activity equivalent to that of T3 at a concentration of about 60 nM. When T4 is used as the substance acting on the thyroid hormone signaling pathway, it can be added to the medium in a range of, for example, 1 nM to 500 μM. Preferably, the range is 50 nM to 50 μM; more preferably, the range is 500 nM to 5 μM. When other thyroid hormone receptor agonists are used, they may ..., so long as they exhibit the same level of agonistic activity as that exhibited by T3 or T4 at the above-mentioned concentrations.
[0088] The medium used in step (E) may contain L-glutamine, taurine, serum, etc., as appropriate. In one example, the medium used in step (E) is a medium to which one or more (preferably all) selected from the group consisting of a substance acting on a BMP signaling pathway, a substance inhibiting an FGF signaling pathway, a substance acting on a Wnt signaling pathway, a substance inhibiting a Wnt signaling pathway, a substance acting on an SHH signaling pathway, a substance inhibiting a TGFβ family signaling pathway, and a substance acting on a TGFβ family signaling pathway.
[0089] In one specific embodiment, a cell aggregate containing a neural retina can be prepared by a method including the following steps (A) to (E): (A) culturing pluripotent stem cells in a medium containing an undifferentiated maintenance factor in the absence of feeder cells and optionally containing a TGFβ family signaling pathway inhibitor and / or a Sonic Hedgehog signaling pathway agonist; (B) forming cell aggregates by suspension culturing the cells obtained in step (A) in a medium that may contain a Wnt signaling pathway inhibitor and / or a Sonic Hedgehog signaling pathway agonist; (C) further culturing the cell aggregates obtained in step (B) in a suspension culture medium containing a substance acting on a BMP signaling pathway; (D) culturing the cell aggregate obtained in step (C) in a serum-free medium or serum medium containing a substance acting on the Wnt signaling pathway and / or a substance inhibiting the FGF signaling pathway for a period of about 2 to 4 days; and (E) A process of culturing the cell aggregates obtained in step (D) for approximately 30 to 200 days in a serum-free medium or a serum-based medium that does not contain a substance active on the Wnt signaling pathway and a substance inhibiting the FGF signaling pathway, and may contain a substance active on the thyroid hormone signaling pathway.
[0090] In one specific embodiment, a cell aggregate containing a neural retina can be prepared by a method including the following steps (A) to (E): (A) culturing pluripotent stem cells for 12 to 48 hours in a medium containing an undifferentiated maintenance factor and containing a TGFβ family signaling pathway inhibitor and / or a Sonic Hedgehog signaling pathway activator in the absence of feeder cells; (B) forming cell aggregates by suspension culturing the cells obtained in step (A) in a medium containing a Wnt signaling pathway inhibitor and / or a Sonic Hedgehog signaling pathway agonist for 12 hours to 72 days (24 hours to 48 hours); (C) a step of suspension-culturing the cell aggregates obtained in step (B) in a medium containing a substance acting on a BMP signaling pathway for an additional 8 to 15 days (10 to 13 days); (D) culturing the cell aggregate obtained in step (C) for 2 to 4 days in a serum-free medium or a serum-containing medium containing a substance acting on the Wnt signaling pathway and / or a substance inhibiting the FGF signaling pathway; and (E) A process of culturing the cell aggregates obtained in step (D) for approximately 10 to 200 days in a serum-free medium or a serum-based medium that does not contain a substance active on the Wnt signaling pathway and a substance inhibiting the FGF signaling pathway, and may contain a substance active on the thyroid hormone signaling pathway.
[0091] Here, step (E) may include culturing the cells in a basal cell proliferation medium for 10 to 30 days, then culturing the cells in a mixed medium of the basal cell proliferation medium and a continuous epithelial tissue maintenance medium containing a thyroid hormone signaling acting substance for 10 to 40 days, and further culturing the cells in a continuous epithelial tissue maintenance medium containing a thyroid hormone signaling acting substance for 20 to 140 days. In one embodiment, step (E) comprises culturing in the presence of a thyroid hormone signaling pathway agonist for 20 to 60 days (30 to 50 days). In one embodiment, the culture period from step (B) to step (E) is 70 days to 100 days (80 days to 90 days).
[0092] The above-mentioned method can produce a cell aggregate containing neural retina, but is not limited thereto. In one embodiment, the cell aggregate containing neural retina can be obtained as a mixture of cell aggregates. In another embodiment, for example, one cell aggregate can be produced in one well of a 96-well plate, and one cell aggregate containing neural retina can be obtained. In either case, cell aggregates produced under the same conditions are considered to be cell aggregates of the same lot. Those skilled in the art can set the cell aggregates of the same lot to any range. For example, cell aggregates contained in the mixture of cell aggregates described above or cell aggregates contained in the same cell culture vessel (e.g., 96-well plate) may be set as cell aggregates of the same lot. As another example, a range using materials such as the same stem cells and medium prepared at the same time can be set as cell aggregates of the same lot. Cell aggregates of the same lot have diversity in terms of cell composition, purity, and morphology. On the other hand, when only a specific tissue (e.g., neural retina) is evaluated from cell aggregates of the same lot, they usually show the same gene expression profile.
[0093] (Cell aggregates that contain the neural retina) The cell aggregate containing the neural retina may have any structure as long as it contains the neural retina. In one embodiment, the cell aggregate containing the neural retina is a sphere-shaped cell aggregate. In one embodiment, a plurality of neural retinas may be present overlapping each other in the cell aggregate containing the neural retina (see, for example, the conceptual diagrams (1) and (2) in FIG. 5). In one embodiment, the cell aggregate containing the neural retina includes a first epithelial tissue (target epithelial tissue) containing a neural retina for transplantation, and a second epithelial tissue (non-target epithelial tissue) having a continuity of the tangent slope of the surface different from the continuity of the tangent slope of the surface of the first epithelial tissue and containing non-neural retinal cells. Here, the first epithelial tissue represents an epithelial tissue that does not substantially contain non-neural retinal cells (non-target cells) and can be used to cut out a neural retina for transplantation. On the other hand, the second epithelial tissue may contain a neural retina, but is an epithelial tissue that is unsuitable for cutting out a neural retina for transplantation because it contains non-target cells. In another embodiment, the cell aggregate comprising the neural retina comprises only a first epithelial tissue (target epithelial tissue) comprising a neural retina for transplantation, and does not comprise a non-target epithelial tissue.
[0094] The neural retina for transplantation is a human neural retina suitable for human transplantation, and preferably consists of neural retina alone. The neural retina for transplantation includes at least a photoreceptor layer, and the photoreceptor layer is formed at least on the outermost side of the cell aggregate. Photoreceptor cells or photoreceptor precursor cells may also be present on the inside, or a photoreceptor layer may also be formed on the inside. The photoreceptor cells, etc. are present continuously in the tangential direction of the surface of the cell aggregate, i.e., adhered to each other, and the photoreceptor cells, etc. are present continuously in the tangential direction of the surface of the cell aggregate to form a photoreceptor layer including photoreceptor cells, etc. The tangential direction refers to the tangential direction to the surface of the cell aggregate, i.e., the direction in which the photoreceptor cells, etc. are arranged in the photoreceptor layer, and refers to a direction parallel or lateral to the neural retina. The inclination of the tangent on the surface of the epithelial tissue refers to the direction in which the cells are arranged when each cell is arranged in a certain direction in the epithelial tissue, and refers to a direction parallel or lateral to the epithelial tissue (or epithelial sheet).
[0095] The second epithelial tissue contained in the cell aggregate is an epithelial tissue other than the neural retina, i.e., an epithelial tissue including extra-target epithelial tissue, and examples of the second epithelial tissue include eye-related tissue and cerebrospinal tissue, and the eye-related tissue means tissue surrounding non-retinal eye tissue, and includes retinal pigment epithelial cells, ciliary body (e.g., ciliary body margin), and lens. The cerebrospinal tissue means neural tissue of the brain and spinal cord, and includes the forebrain, telencephalon, cerebrum, diencephalon, hypothalamus, midbrain, hindbrain, cerebellum, and spinal cord. The cells and expressed genes contained in the second epithelial tissue are described below.
[0096] Examples of cell aggregates containing a first epithelial tissue and a second epithelial tissue include cell aggregates shown in the conceptual diagram in FIG. 4 and the conceptual diagrams (3) and (5) in FIG. 5. The conceptual diagram in FIG. 4 shows an example of a cell aggregate in which eye-related tissues (retinal pigment epithelial cells, ciliary body) (black part in FIG. 4) exist as the second epithelial tissue in a part of the neural retina, which is the first epithelial tissue. The conceptual diagram (3) in FIG. 5 shows an example of a cell aggregate in which eye-related tissues (retinal pigment epithelial cells, ciliary body) (black part in FIG. 5(3)) exist as the second epithelial tissue in a case where a plurality of neural retinas are overlapped (e.g., conceptual diagrams (1) and (2) in FIG. 5). The conceptual diagram (5) in FIG. 5 shows an example of a cell aggregate in which cerebrospinal tissues (such as the cerebrum) (gray part in FIG. 5(5)) exist as the second epithelial tissue. As shown in the conceptual diagram (4) in FIG. 5, there are cases in which non-target tissues are included inside the cell aggregate containing the neural retina for transplantation. In this case, the definition of "having a continuity of the slope of the tangent of the surface different from the continuity of the slope of the tangent of the surface of the first epithelial tissue" is not met, and therefore the tissue does not fall under the category of the second epithelial tissue. The neural retina for transplantation and the sample for quality evaluation are preferably selected from cell aggregates that do not contain any non-target tissue inside.
[0097] <Extraction process> The method for evaluating the quality of a neural retina for transplantation according to the present invention includes sampling a part or the whole of a cell aggregate containing a neural retina having an epithelial structure derived from pluripotent stem cells as a sample for quality evaluation (hereinafter referred to as an "extraction step"). Extracting a part of a cell aggregate as a sample for quality evaluation means selecting a part of cell aggregates (one or more) or all of the cell aggregates from a plurality of cell aggregates, and isolating (e.g., dissecting) a part of the selected cell aggregate as a sample for evaluation using tweezers, scissors, and / or a knife or the like. Extracting the whole of a cell aggregate as a sample for quality evaluation means selecting a part of cell aggregates (one or more) from a plurality of cell aggregates, and picking up all of the selected one or more cell aggregates separately as a sample for quality evaluation. When selecting one or more cell aggregates from a plurality of cell aggregates, it is preferable to randomly extract them. In this specification, a cell aggregate in which a portion of a cell aggregate is extracted as a sample for quality assessment is referred to as a "cell aggregate including a sample for quality assessment," and a cell aggregate in which the entire cell aggregate is extracted as a sample for quality assessment is referred to as a "cell aggregate of a sample for quality assessment."
[0098] (Extraction of whole cell aggregates) In one embodiment, the quality assessment sample is the whole of a cell aggregate containing a neural retina having an epithelial structure derived from pluripotent stem cells. To perform quality assessment of cell aggregates containing neural retina of the same lot, the quality assessment sample may be the whole of one or more cell aggregates in the cell aggregate of the same lot. Here, the mixture of cell aggregates of the same lot includes, for example, 2 to 10,000 cell aggregates.
[0099] Specifically, in quality evaluation of cell aggregates contained in the same lot, one or more cell aggregates are selected from the same lot, and all of the selected one or more cell aggregates are extracted as a quality evaluation sample. When all of the selected one or more cell aggregates are used as a quality evaluation sample, all of the multiple cell aggregates may be extracted together, or all of the multiple cell aggregates may be extracted separately. The cell aggregates of the quality evaluation sample used for the quality evaluation will no longer be usable for transplantation.
[0100] If, as a result of the judgment using the quality assessment sample, all of the cell aggregates as one or more quality assessment samples are judged to be usable as neural retina for transplantation, it can be judged that the neural retina in cell aggregates other than the quality assessment sample of the same lot, which are manufactured under conditions showing a gene expression profile equivalent to that of the neural retina for transplantation contained in the cell aggregate, can be used as neural retina for transplantation, and the epithelial tissue including the neural retina contained in these other cell aggregates can be used for transplantation (also called same-lot evaluation). Therefore, the extraction method is useful for efficient quality assessment.
[0101] As a result of the judgment using the quality evaluation sample, if any one of the cell aggregates as the multiple quality evaluation samples is judged to be unusable as a neural retina for transplantation, the neural retina in the other cell aggregates of the same lot is judged to be unusable as a neural retina for transplantation. Therefore, for example, when the number of samples in the same lot is large and the possibility of inappropriate samples being mixed is low, this method (same lot evaluation) is usually used. However, since the whole cell aggregate is extracted as the evaluation sample, it is preferable not to use this method for a lot containing a cell aggregate containing a second epithelial tissue. In this case, it is more appropriate to extract and evaluate a part of the cell aggregate (neural retina) described later, rather than the whole cell aggregate. In addition, for a lot containing a cell aggregate containing a second epithelial tissue, the total number evaluation described later is preferably used rather than the same lot evaluation.
[0102] (Extraction of part of cell aggregates) In one embodiment, the quality assessment sample is a part of a cell aggregate containing a neural retina having an epithelial structure derived from pluripotent stem cells. By extracting a part of the cell aggregate as the quality assessment sample, there is an advantage that the cell aggregate is not completely destroyed and the neural retina contained in the remaining part can be used for transplantation. In other words, if the quality assessment sample, which is a part of the cell aggregate, is judged to be acceptable by the judgment process described below, the neural retina having an epithelial structure in the cell aggregate containing the quality assessment sample can be used as a neural retina for transplantation and can be used for transplantation.
[0103] In one embodiment, the extraction method can be used to individually evaluate the quality of cell aggregates containing neural retina (also called individual evaluation). In this case, there is an advantage that all cell aggregates containing neural retina to be evaluated can be selected and the quality of all of them can be evaluated (total evaluation). The evaluation method (individual evaluation / total evaluation) can be said to be the most accurate quality evaluation method because it can individually evaluate the quality of neural retina for transplantation. On the other hand, when the number of samples is large, it requires a lot of labor and cost. Note that the evaluation method is premised on the existence of a site (quality evaluation sample) that shows a gene expression profile equivalent to that of the neural retina in the site excluding the neural retina for transplantation in the cell aggregate of 1, and on the ability to cut out the quality evaluation sample. In particular, whether the premise is met in the cell aggregate containing the second epithelial tissue is a major issue. The present inventors have found for the first time by evaluating a large number of samples that cell aggregates containing neural retina meet the premise and that the evaluation method can be used.
[0104] In order to utilize the above advantages, it is preferable that the part of the cell aggregate extracted as the quality evaluation sample does not include the neural retina for transplantation or a candidate for the neural retina for transplantation. It is also preferable that the quality evaluation sample is a part that shows a gene expression profile equivalent to that of the neural retina for transplantation or a candidate for the neural retina for transplantation. In order for the neural retina for transplantation and the quality evaluation sample to show a gene expression profile equivalent to that of the neural retina for transplantation, it is preferable that the quality evaluation sample is at least partially adjacent to or continuous with the neural retina for transplantation, and is preferably included in the same epithelial tissue as the neural retina for transplantation. It is also preferable that the neural retina for transplantation includes the vicinity of the center of the same epithelial tissue as the best part (e.g., containing neural retina and not containing non-neural retina, and having a continuous epithelial structure) in the cell aggregate, and it is preferable that the vicinity of the center of the same epithelial tissue and have the size described in the [neural retina sheet for transplantation] described later. Therefore, it is preferable that the quality evaluation sample does not include the vicinity of the center of the same epithelial tissue. Here, the same epithelial tissue means a continuous epithelial tissue with continuity in the slope of the tangent on the surface of the epithelial tissue, and the same epithelial tissue is preferably a continuous epithelial tissue. Here, the vicinity of the center of epithelial tissue (continuous epithelial tissue) refers to a portion on the surface of the same epithelial tissue that is equidistant from both ends, and can be estimated by a person skilled in the art through observation under a microscope. The quality assessment sample is preferably a portion that is continuous or adjacent to the portion used as the neural retina for transplantation (e.g., a portion used for transplantation that includes the vicinity of the center of one epithelial tissue), and is as narrow as possible within the range in which quality assessment is possible. For example, the neural retina for transplantation is a portion near the center of the same epithelial tissue, and the quality assessment sample is a portion of the same epithelial tissue that is at least partially continuous or adjacent to the neural retina for transplantation.
[0105] In one embodiment of the individual evaluation and / or total evaluation, when the cell aggregate containing the neural retina for transplantation includes a first epithelial tissue containing the neural retina for transplantation, and an extra-target epithelial tissue (second epithelial tissue) having a continuity of the tangent slope of the surface different from the continuity of the tangent slope on the surface of the first epithelial tissue and containing extra-target cells, the neural retina for transplantation preferably includes a region on the first epithelial tissue farthest from the extra-target epithelial tissue, and in this case, the quality evaluation sample may be a part present between the extra-target epithelial tissue and the neural retina for transplantation. The region on the first epithelial tissue farthest from the extra-target epithelial tissue is, for example, a region including a point on the periphery of the first epithelial tissue when the straight line is drawn from the center of the extra-target epithelial tissue to the periphery of the first epithelial tissue, in which the length is the longest. Furthermore, the quality evaluation sample is a portion adjacent to or continuous with the neural retina for transplantation (for example, a portion used for transplantation including the vicinity of the center of one epithelial tissue), and is preferably as narrow as possible within the range where quality evaluation is possible. An example of a graft and a sample for quality evaluation is a conceptual diagram of FIG. 4.
[0106] In another embodiment, in order to perform quality evaluation of cell aggregates containing neural retina of the same lot (same lot evaluation), instead of the whole of one or more cell aggregates in the cell aggregates of the same lot, a part of one or more cell aggregates in the cell aggregates of the same lot can be extracted as a quality evaluation sample. That is, one or more cell aggregates can be selected from the cell aggregates of the same lot, and only a part cut out from the selected cell aggregate can be used as a quality evaluation sample. In particular, the extraction method is useful when the whole cannot be used for quality evaluation, such as a cell aggregate containing a second epithelial tissue, and when it is desired to perform quality evaluation efficiently. In this case, it is preferable to use a neural retina for transplantation as the quality evaluation sample. The neural retina for transplantation used as the quality evaluation sample here refers to the neural retina in the cell aggregate produced under conditions that show a gene expression profile equivalent to that of the retina for transplantation. By using the part that would have been used as the neural retina for transplantation if not extracted as the quality evaluation sample for quality evaluation, it is possible to more accurately perform quality evaluation of other cell aggregates containing neural retina for transplantation of the same lot.
[0107] In the cell aggregate, a part having a continuous epithelial structure and having an outer neuroblastic layer and an inner neuroblastic layer that are separated into two layers can be determined as the neural retina. On the other hand, the eye-related tissue as the second epithelial tissue, particularly the retinal pigment epithelial cells, is black when observed visually or under a microscope, and therefore can be easily distinguished from the neural retina by a person skilled in the art. In addition, the cerebrospinal tissue as the second epithelial tissue can be easily distinguished from the neural retina by a person skilled in the art, by focusing on the morphological characteristics, such as the fact that a continuous epithelial structure cannot be confirmed on the surface of the cell aggregate, the fact that the morphological characteristics specific to the neural retina cannot be confirmed, and / or the fact that the color tone appears dull, when observed visually or under a microscope. Therefore, even if the cell aggregate contains the second epithelial tissue, a person skilled in the art can isolate the neural retina for transplantation and a sample for quality evaluation from the first epithelial tissue containing the neural retina.
[0108] As described above, in one embodiment, a quality assessment sample is set and extracted based on a certain positional relationship with the neural retina for transplantation or a candidate for the neural retina for transplantation. That is, the region to be cut out as the quality assessment sample can be determined by setting the neural retina for transplantation or its candidate. Here, in one embodiment, the neural retina for transplantation (also called a graft or a cap) and its candidate can be specified by its position in the above-mentioned cell aggregate (e.g., near the center of the epithelial tissue (continuous epithelial tissue), and in the case of having a second epithelial tissue, the region on the first epithelial tissue further away from the second epithelial tissue), and the size described in the section on [Neural retina sheet for transplantation] below. Therefore, a person skilled in the art can set a neural retina having the characteristics as a neural retina for transplantation or its candidate.
[0109] When extracting a neural retina for transplantation and a quality assessment sample from the same cell aggregate, a person skilled in the art can set the quality assessment sample (also called a ring) as an area that is at least partially continuous or adjacent to the neural retina for transplantation set as described above, and as narrow as possible within the range where quality assessment is possible. When extracting a part of one or more cell aggregates in the cell aggregate of the same lot as a quality assessment sample, a person skilled in the art can extract the above-mentioned neural retina for transplantation or a candidate thereof from the cell aggregate. In this case, the size of the cut-out sample for quality assessment may be the size described in the [neural retina sheet for transplantation] described later, or may be even smaller. Therefore, the quality assessment sample can be set and extracted based on the relationship with the position of the neural retina for transplantation or a candidate thereof and the above-mentioned size.
[0110] <Detection process> The method for evaluating the quality of neural retina for transplantation according to the present invention includes detecting the expression of neural retinal cell-related genes and non-neural retinal cell-related genes (non-target cell-related genes) in a quality evaluation sample (detection step). The detection step preferably quantitatively detects the expression levels of the genes. The non-target cell-related genes include one or more genes selected from the group consisting of cerebrospinal tissue marker genes and eyeball-related tissue marker genes.
[0111] (Neural retinal cell-related genes) The neural retinal cell-related gene (target cell-related gene) refers to a gene expressed by neural retinal cells. As the neural retinal cell-related gene, a gene that is highly expressed in photoreceptors (rod photoreceptors, cone photoreceptors), horizontal cells, amacrine cells, interneurons, retinal ganglion cells (ganglion cells), bipolar cells (rod bipolar cells, cone bipolar cells), Muller glial cells, or precursor cells of these cells, neural retinal progenitor cells, etc., compared to non-target cells is preferred. As the neural retinal cell-related gene, the above-mentioned neural retinal cell markers can be mentioned, and RAX, Chx10, SIX3, SIX6, RCVRN, CRX, NRL and NESTIN are preferred. The GenBank IDs of the neural retinal cell markers are shown in Table 1 below. [Table 1]
[0112] The neural retinal cell-associated genes are preferably, but not limited to, those listed in Table 1. Other neural retinal cell-associated genes include Rax2, Vsx1, Blimp1, RXRG, S-opsin, M / L-opsin, Rhodopsin, Brn3, L7, etc.
[0113] (Non-neural retinal cell-related genes) There was absolutely no knowledge of unintended cells induced as by-products in the process of producing cell aggregates containing neural retina as pharmaceutical raw materials, and of methods for detecting the unintended cells for the quality evaluation of pharmaceuticals. In the process of diligently studying a method for continuously producing neural retina of a quality that meets the standards for pharmaceutical raw materials, the present inventors found cells or tissues that may be produced as by-products, and found non-neural retinal cell-associated genes (unintended cell-associated genes) as genes that can be used to efficiently and effectively identify and evaluate the quality of neural retina.
[0114] In one embodiment, the non-neural retinal cell-related gene (non-target cell-related gene) may include a cerebrospinal tissue marker gene and an eyeball-related tissue marker gene. In one embodiment, the non-neural retinal cell-related gene may include an undifferentiated iPS cell marker gene.
[0115] In one embodiment, the cerebrospinal tissue marker gene may be one or more genes selected from the group consisting of a telencephalon marker gene, a diencephalon / mesencephalon marker gene, and a spinal cord marker gene. The diencephalon / mesencephalon marker gene may be one or more genes selected from the group consisting of a diencephalon marker gene, a mesencephalon marker gene, and a hypothalamic marker gene related to the hypothalamus, which is a part of the diencephalon.
[0116] In one embodiment, the eye-related tissue marker gene may be one or more genes selected from the group consisting of an optic stalk marker gene, a ciliary body marker gene, a lens marker gene, and a retinal pigment epithelium marker gene.
[0117] The telencephalic marker gene refers to a gene expressed in the telencephalon. The telencephalic marker gene may include one or more genes selected from the group consisting of FoxG1 (also known as Bf1), Emx2, Dlx2, Dlx1, and Dlx5. The GenBank IDs of the telencephalic marker genes are shown in Table 2 below. [Table 2]
[0118] The telencephalic marker gene is preferably, but not limited to, the genes listed in Table 2. Other telencephalic marker genes include Emx1, LHX2, LHX6, LHX7, Gsh2, etc.
[0119] The diencephalon / midbrain marker gene means a gene expressed in the diencephalon and / or midbrain. The diencephalon / midbrain marker gene may include one or more genes selected from the group consisting of OTX1, OTX2, and DMBX1. GenBank IDs of the diencephalon / midbrain marker genes are shown in Table 3 below. The diencephalon / midbrain marker gene may include a hypothalamic marker described below with respect to the hypothalamus, which is a region of the diencephalon. That is, the diencephalon / midbrain marker gene may include one or more genes selected from the group consisting of OTX1, OTX2, OTX2, DMBX1, Rx, Nkx2.1, OTP, FGFR2, EFNA5, and GAD1. [Table 3]
[0120] The hypothalamic marker gene refers to a gene expressed in the hypothalamus. The hypothalamic marker gene may include one or more genes selected from the group consisting of Rx, Nkx2.1, Dmbx1, OTP, gad1, FGFR2 and EFNA5. The GenBank IDs of the hypothalamic marker genes are shown in Table 4 below. [Table 4]
[0121] The spinal cord marker gene refers to a gene expressed in the spinal cord. The spinal cord marker gene may include one or more genes selected from the group consisting of HoxB2, HoxA5, HOXC5, HOXD1, HOXD3 and HOXD4. The GenBank IDs of the spinal cord marker genes are shown in Table 5 below. [Table 5]
[0122] The spinal cord marker genes are preferably, but not limited to, those listed in Table 2. Other examples of spinal cord marker genes include genes that form Hox clusters.
[0123] On the other hand, in one embodiment, when retinoic acid is used in the manufacturing process, the expression of HOX genes (e.g., HOXC5, HOXA5, and HOXB2) may be observed even when good retinal tissue is produced. The expression of HOX genes is thought to be controlled by retinoic acid signals, and HOX gene expression increases to a degree that does not affect the differentiation induction of retinal tissue. The effect of this retinoic acid signal is thought to be due to promoting posteriorization along the anterior-posterior axis. Therefore, when retinoic acid is used in the manufacturing process (especially when retinoic acid is used after the start of differentiation induction into retina), HOX genes (e.g., HOXC5, HOXA5, and HOXB2) are excluded from the genes to be evaluated for quality, or the quality of the neural retina for transplantation can be determined to be good even if the expression of these genes is observed.
[0124] The term "optical stalk marker gene" refers to a gene expressed in the optic stalk. The optic stalk marker gene may include one or more genes selected from the group consisting of GREM1, GPR17, ACVR1C, CDH6, Pax2, Pax8, GAD2 and SEMA5A. The GenBank IDs of the optic stalk marker genes are shown in Table 6 below. [Table 6]
[0125] The lens marker gene refers to a gene expressed in the lens. The lens marker gene may include one or more genes selected from the group consisting of CRYAA and CRYBA1. The GenBank IDs of the lens marker genes are shown in Table 7 below. [Table 7]
[0126] The ciliary body marker gene refers to a gene expressed in the ciliary body, the ciliary margin, and / or the ciliary body. The ciliary body marker gene may include one or more genes selected from the group consisting of Zic1, MAL, HNF1beta, FoxQ1, CLDN2, CLDN1, GPR177, AQP1, and AQP4. The GenBank IDs of the ciliary body marker genes are shown in Table 8 below. [Table 8]
[0127] The retinal pigment epithelium marker gene refers to a gene expressed in the retinal pigment epithelium cell. The retinal pigment epithelium marker gene includes the above-mentioned retinal pigment epithelium marker, and may include one or more genes selected from the group consisting of MITF, TTR, and BEST1. The GenBank ID of the retinal pigment epithelium marker gene is shown in Table 9 below. [Table 9]
[0128] In one embodiment, the non-target cell-related genes may further include undifferentiated pluripotent stem cell marker genes.
[0129] The undifferentiated pluripotent stem cell marker gene may include one or more genes selected from the group consisting of Oct3 / 4, Nanog, and lin28. Preferably, the undifferentiated pluripotent stem cell marker gene is one or more genes selected from the group consisting of Oct3 / 4, Nanog, and lin28. The GenBank IDs of the undifferentiated pluripotent stem cell marker genes are shown in Table 10 below. [Table 10]
[0130] (Detection method) In one embodiment, the detection of the expression of neural retinal cell-related genes and non-neural retinal non-target cell-related genes includes, but is not limited to, Western blotting, immunostaining, flow cytometry analysis / flow cytometer (FACS (registered trademark, manufactured by BD), etc.), Northern blotting, electrophoresis, PCR (preferably, quantitative PCR (qPCR) and / or real-time PCR), gene chip analysis, next-generation sequencer, and other techniques. Among these, quantitative PCR is useful in terms of quantitation, detection sensitivity, stability of results, and speed. Furthermore, by applying a device used for single-cell quantitative PCR (e.g., Biomark HD (manufactured by Fluidigm), etc.) to normal quantitative PCR, it is possible to evaluate multiple quality evaluation samples in a short time. In particular, when performing a total evaluation, particularly when the number of samples used for quality evaluation and the number of genes to be evaluated are large, the method allows rapid quality evaluation.
[0131] In one embodiment, the expression levels of each of neural retinal cell-related genes and non-neural retinal cell-related genes in two or more quality assessment samples may be simultaneously detected by quantitative PCR. The quantitative PCR may be performed, for example, by a method including the following steps (1) to (5). (1) preparing a flow path plate having a sample well group consisting of one group of 8 to 800 independent sample wells, a primer well group consisting of one or more groups of 8 to 800 independent primer wells, and flow paths connecting the independent sample wells in the sample well group and the independent primer wells in each primer well group, a solution containing nucleic acid obtained from two or more of the above quality assessment samples (sample solution), and a solution containing one or more primers specific to one or more of the above neural retinal cell-related genes or the above non-neural retinal cell-related genes (primer solution); (2) adding the sample solution to each of the quality evaluation samples in a sample well group so that one sample solution per one sample well is added; (3) adding the primer solution to one or more primer wells in the one or more primer well groups so that the primer well groups are different; (4) separately mixing the primer with the nucleic acid through the flow path; and (5) Perform quantitative PCR using the mixture obtained in (4).
[0132] A solution containing nucleic acids obtained from two or more quality assessment samples can be prepared by reverse transcription reaction of RNA extracted from the quality assessment samples using reverse transcriptase and primers. Those skilled in the art can appropriately perform RNA extraction and reverse transcription reaction using well-known techniques. In addition, those skilled in the art can prepare primers that can amplify the genes to be quantified according to the genes to be quantified.
[0133] In one embodiment, the solution containing nucleic acid (sample solution) may be a solution that has been subjected to a multiplex-PCR reaction (pre-run) using all primers to be used by a PCR device before being added to each well of the sample well group. The pre-run amplifies the nucleic acid to a certain extent, making it possible to effectively perform quantitative PCR. As a condition for the pre-run, for example, the solution containing nucleic acid is subjected to a PCR reaction for about 10 to 15 cycles using all primers to be used.
[0134] In one embodiment, a flow path plate having a flow path connecting the above-mentioned different well groups may be used for quantitative PCR. On the flow path plate, there are a flow path (for example, an integrated fluid circuit), a plurality of wells for adding a solution containing nucleic acid, and a plurality of wells for adding a primer, and each well may be connected to one or a plurality of flow paths (integrated fluid circuits). A solution containing nucleic acid and a primer are added to each well one by one. In one embodiment, a well-known device (for example, an IFC controller HX, an IFC controller MX, an IFC controller RX, all manufactured by Fluidigm) is used to apply air pressure to the wells, thereby allowing the solution containing nucleic acid and the primer added to each well to flow into the flow path (integrated fluid circuit). The flow path (integrated fluid circuit) may have a structure in which, for example, a sample solution and a primer solution are mixed one to one. This allows the mixture of sample solution and primer solution to be prepared at one time for the number of combinations of sample solution and primer solution (for example, when 96 sample solutions and 96 primer solutions are used, the number of combinations is 96×96=9216). After preparing the mixture, the flow channel plate is subjected to a quantitative PCR reaction in a quantitative PCR device (eg, Biomark HD), whereby the expression levels of each gene in the solution containing each nucleic acid can be measured simultaneously.
[0135] Also useful is flow cytometry analysis using a flow cytometer capable of detecting the proportion of expressing cells. In recent years, the detection speed has been improved, and flow cytometers (FACS (registered trademark) and the like) capable of evaluating a large number of samples with high throughput are now available. Therefore, the use of a high-throughput flow cytometer is also useful for detecting the expression of neural retinal cell-related genes and non-neural retinal non-target cell-related genes. Such high-throughput flow cytometers can be commercially available products (e.g., MACSQuant (registered trademark) Analyzers, manufactured by Miltenyi Biotec).
[0136] <Judgment process> The method according to the present invention includes, when expression of neural retinal cell-related genes is observed and expression of non-neural retinal cell-related genes is not observed, determining that the epithelial tissue (neural retina for transplantation) containing neural retina in the cell aggregate containing the sample for quality assessment, which is a part of the above, and the epithelial tissue (neural retina for transplantation) containing neural retina in the cell aggregate of the same lot as the cell aggregate of the sample for quality assessment, which is the whole of the above, can be used as neural retina for transplantation (determination step). Here, being usable as neural retina for transplantation means that the neural retina is suitable for transplantation, and is also referred to as being suitable as neural retina for transplantation or being acceptable as neural retina for transplantation.
[0137] The expression of a neuroretinal cell-related gene is observed means that the expression of a neuroretinal cell-related gene is observed at a level that is substantially detectable by the detection method for gene expression (e.g., above the lower limit of detection). The expression of a non-neural retinal cell-related gene is not observed means that the expression of a non-neural retinal cell-related gene cannot be substantially detected by the detection method for gene expression (e.g., below the lower limit of detection). Substantial detectability means that the gene is detected beyond a level at which it cannot be said that the gene is substantially functional. Those skilled in the art can appropriately set the level depending on the gene and the detection method. For example, in the case of a quantitative gene expression detection method, the range of more than 0% to 10% or more than 0% to 5% based on the lower limit of detection of the gene expression can be judged as not being substantially detectable (i.e., the expression of the gene cannot be detected).
[0138] In one aspect, it is preferable to determine that the tissue can be used as a neural retina for transplantation when the following criteria 1 and 2 are met in the quantitative PCR method. Criterion 1: The difference (ΔCt value) between the threshold cycle (Ct) value of the neural retinal cell-related gene and the Ct value of the internal standard gene is 10 or less. Criterion 2: The difference between the Ct value of the non-neural retinal cell-related gene and the Ct value of the internal control gene (ΔCt value) is 5 or more.
[0139] The threshold cycle (Ct) value means the number of cycles at which a constant amount of amplified product is obtained in the region where gene amplification by PCR occurs exponentially. The Ct value is inversely correlated with the initial amount of gene, and is therefore used to calculate the initial copy number of gene. In one embodiment, the "2^Ct value (2 to the power of the Ct value)" is inversely proportional to the initial amount of gene, and is therefore used to calculate the initial copy number of gene. Specifically, a sample containing twice the initial amount of gene will have a Ct value one cycle earlier than a sample containing only half the copy number of gene before amplification. The constant amount of amplified product may be within the region where gene amplification by PCR occurs exponentially, and can be set by a person skilled in the art.
[0140] The internal standard gene refers to a gene whose expression level differs little between samples. As the internal standard gene, any gene known to those skilled in the art can be appropriately used, such as 18S ribosomal RNA, β-actin, HPRT, α-tubulin, transferrin receptor, ubiquitin, GAPDH, etc., and preferably GAPDH.
[0141] The Ct value is inversely correlated with the initial amount of the gene, and therefore depends on the expression level of the gene in the cell. That is, when the concentration of the nucleic acid-containing solution is constant, the Ct value varies depending on the internal standard gene used, and the difference between the Ct value of a specific gene and the Ct value of the internal standard gene (ΔCt value) is affected by the internal standard gene used. In this specification, the ΔCt value is described based on the value when GAPDH is used as the internal standard gene, unless otherwise specified.
[0142] When an internal standard gene other than GAPDH is used as the internal standard gene, the ΔCt values of the above criteria 1 and 2 can be corrected by comparing the expression levels of GAPDH and the internal standard gene other than GAPDH.
[0143] In one embodiment, when β-actin is used as an internal standard gene, in the production method of the present application, the Ct value of GAPDH is about 1 lower than the Ct value of β-actin, that is, the absolute amount of GAPDH RNA is about twice the absolute amount of β-actin RNA. Criterion 1: The difference (ΔCt value) between the threshold cycle (Ct) value of the neural retinal cell-related gene and the Ct value of the internal standard gene is 9 or less. Criterion 2: The difference between the Ct value of the non-neural retinal cell-related gene and the Ct value of the internal control gene (ΔCt value) is 4 or more It can be said that:
[0144] In one embodiment, when HPRT is used as an internal standard gene, in the production method of the present application, the Ct value of GAPDH is about 7 times lower than that of HPRT, that is, the absolute amount of GAPDH RNA is about 2^7 (2 to the power of 7, 128 times) the absolute amount of HPRT RNA. Criterion 1: The difference (ΔCt value) between the threshold cycle (Ct) value of the neural retinal cell-related gene and the Ct value of the internal control gene is 3 or less. Criterion 2: The difference between the Ct value of the non-neural retinal cell-related gene and the Ct value of the internal control gene (ΔCt value) is -2 or more It can be said that:
[0145] The neural retinal cell-related gene may be any of the above-mentioned genes. There are a plurality of neural retinal cell-related genes. That is, even when extracted from the same neural retinal cell, the Ct value of the reference value 1 may differ depending on the type of neural retinal cell-related gene. A person skilled in the art can set a ΔCt value that allows for determining whether the neural retinal cell-related gene is expressed for each gene based on publicly known information such as the expression site and expression level of the neural retinal cell-related gene.
[0146] For example, for the Chx10 gene, when GAPDH is used as an internal standard, the ΔCt value may be 20 or less, preferably 15 or less, and more preferably 10 or less.
[0147] For example, for the Recoverin gene, when GAPDH is used as an internal standard, the ΔCt value may be 16 or less, preferably 11 or less, and more preferably 6 or less.
[0148] In general, the difference (ΔCt value) between the Ct value of the neuroretinal cell-associated gene and the Ct value of the internal standard gene (e.g., GAPDH) may be, for example, 25 or less, 20 or less, 15 or less, or 10 or less. The difference between the Ct value of the neuroretinal cell-associated gene and the Ct value of the internal standard gene may be, for example, -10 or more, -5 or more, 0 or more, or 5 or more.
[0149] The non-neural retinal cell-related gene may be any of the above-mentioned genes. There are a plurality of genes as the non-neural retinal cell-related gene. That is, even when extracted from the same non-retinal cell, the Ct value differs depending on the non-neural retinal cell-related gene. A person skilled in the art can set a ΔCt value that can determine that the neural retinal cell-related gene is expressed for each gene based on publicly known information such as the expression site and expression level of the non-neural retinal cell-related gene. For example, when GAPDH is used as the internal standard for the PAX2 gene, the ΔCt value may be 5 or more. When GAPDH is used as the internal standard for the HOXB2 gene, the ΔCt value may be 5 or more. In general, the difference between the Ct value of the non-neural retinal cell-related gene and the Ct value of the internal standard gene may be 30 or less, 25 or less, or 20 or less. In addition, the difference between the Ct value of the non-neural retinal cell-related gene and the Ct value of the internal standard gene may be, for example, 0 or more, 3 or more, or 5 or more.
[0150] The above-mentioned quality evaluation method can be used as a quality control method for a pharmaceutical product (neural retina for transplantation) or as a quality control technique in the manufacturing process of a pharmaceutical product (neural retina for transplantation).
[0151] [Neural retina sheet for transplantation] One aspect of the present invention is a neural retina sheet for transplantation, comprising: (1) Derived from pluripotent stem cells; (2) has a three-dimensional structure; (3) A neural retina layer having a multi-layer structure including a photoreceptor layer and an inner layer, (4) the photoreceptor layer comprises one or more cells selected from the group consisting of photoreceptor precursor cells and photoreceptor cells; (5) The inner layer comprises one or more cells selected from the group consisting of retinal progenitor cells, ganglion cells, amacrine cells, and bipolar cells; (6) the surface of the neural retinal layer has an apical surface; (7) There is an inner layer inside the layer of photoreceptors along the apical surface, (8) The area of the neural retinal layer is 50% or more of the total surface area of the neural retinal sheet for transplantation; (9) The area of the continuous epithelial structure is 80% or more of the total area of the apical surface of the neural retina layer; (10) Expression of neural retinal cell-related genes in a neural retinal sheet for transplantation is observed, and expression of non-neural retinal cell-related genes is not observed, and the non-neural retinal cell-related genes include one or more genes selected from the group consisting of cerebrospinal tissue marker genes and eyeball-related tissue marker genes. The present invention relates to a neural retina sheet for transplantation.
[0152] In one embodiment, the neural retina sheet for transplantation is a neural retina for transplantation cut out by the above-mentioned quality evaluation method. Therefore, the characteristics of the neural retina sheet for transplantation described below also correspond to the characteristics of the neural retina for transplantation cut out by the above-mentioned quality evaluation method.
[0153] The neural retinal sheet for transplantation includes (3) a neural retinal layer having a multi-layer structure including a photoreceptor layer and an inner layer. As described in (6) and (7), the photoreceptor layer is present on the outside (surface) of the neural retinal sheet for transplantation, but an ectopic photoreceptor layer may also be present in the inner layer.
[0154] The neural retina sheet for transplantation has an inner layer (5) that contains one or more cells selected from the group consisting of retinal progenitor cells, ganglion cells, amacrine cells, and bipolar cells, and may contain one or more cells selected from the group consisting of ectopic photoreceptor progenitor cells and photoreceptor cells. In one embodiment, there is also provided a neural retina sheet for transplantation in which the content of ganglion cells, amacrine cells, and horizontal cells is 30% or less of the total number of cells, a neural retina sheet for transplantation in which the content of ganglion cells, amacrine cells, horizontal cells, and bipolar cells is 30% or less of the total number of cells, and / or a neural retina sheet for transplantation in which the content of bipolar cells is 10% or less of the total number of cells.
[0155] In the neural retina sheet for transplantation, (8) the area of the neural retina layer is 40% or more, preferably 50% or more, more preferably 60% or more of the total area of the surface of the neural retina sheet for transplantation. In the neural retina sheet for transplantation, (9) the area of the continuous epithelial structure is 60% or more, preferably 70% or more, more preferably 80% or more of the total area of the apical surface of the neural retina layer.
[0156] The neural retinal cell-associated genes and non-neural retinal cell-associated genes (cerebrospinal tissue marker genes and eyeball-associated tissue marker genes) are the genes described above.
[0157] (10) Whether or not expression of neural retinal cell-related genes in a neural retinal sheet for transplantation is observed and whether or not expression of non-neural retinal cell-related genes is observed can be ascertained by taking a part of the neural retinal sheet for transplantation and detecting gene expression. In addition, if the neural retinal sheet for transplantation is isolated from a cell aggregate in which expression of neural retinal cell-related genes is substantially observed and expression of non-neural retinal cell-related genes is substantially not observed in a quality evaluation sample by the above-mentioned method for evaluating the quality of the neural retina for transplantation, detection of gene expression in the neural retinal sheet for transplantation itself is not necessary. As described above, whether or not expression of the gene is substantially observed is determined by whether or not the expression is at a level that is substantially detectable by the method for detecting gene expression.
[0158] The neural retinal cell-associated gene in the neural retina sheet for transplantation may be, for example, one or more selected from the group consisting of Rx, Chx10, Pax6, and Crx. The ratio of cells expressing a neural retinal cell-associated gene (positive cells) to the total number of cells varies depending on the differentiation stage of the neural retina.
[0159] In one embodiment, the ratio of Rx positive cells to the total number of cells in the neural retina sheet for transplantation may be 30% or more, 40% or more, 50% or more, or 60% or more. In one embodiment, the ratio of Chx10 positive cells or Pax6 positive cells to the total number of cells in the neural retina sheet for transplantation may be 10% or more, 20% or more, 30% or more, 40% or more, or 50% or more. In one embodiment, the ratio of Crx positive cells to the total number of cells in the neural retina sheet for transplantation may be 10% or more, 20% or more, 30% or more, 40% or more, or 50% or more.
[0160] In one embodiment, the ratio of Rx positive cells to the total number of cells in the neural retina sheet for transplantation may be 30% to 80%, 40% to 70%, 45% to 60%, or 50% to 60%. In one embodiment, the ratio of Chx10 positive cells or Pax6 positive cells to the total number of cells in the neural retina sheet for transplantation may be 10% to 80%, 20% to 70%, 30% to 60%, or 40% to 50%. In one embodiment, the ratio of Crx positive cells to the total number of cells in the neural retina sheet for transplantation is 10% to 70%, 10% to 60%, 20% to 60%, 30% to 60%, 40% to 60%, or 50% to 60%.
[0161] In one aspect, (1) the proportion of Chx10-positive and Pax6-positive cells (neural retinal progenitor cells) relative to the total number of cells in the neural retina sheet for transplantation may be 10% or more and 50% or less, or 10% or more and 30% or less, (2) the proportion of Chx10-positive and Pax6-negative cells (progenitor cells biased toward bipolar cells) may be 10% or more and 25% or less, or 15% or more and 25% or less, and (3) the proportion of Chx10-negative and Pax6-positive cells (ganglion cells and amacrine cells) may be 10% or more and 25% or less, or 10% or more and 20% or less.
[0162] In another aspect, (1) the proportion of Chx10-positive and Pax6-positive cells (neural retinal progenitor cells) relative to the total number of cells in the neural retina sheet for transplantation may be 20% or more and 40% or less, (2) the proportion of Chx10-positive and Pax6-negative cells (progenitor cells biased toward bipolar cells) may be 5% or more and 20% or less, and (3) the proportion of Chx10-negative and Pax6-positive cells (ganglion cells and amacrine cells) may be 5% or more and 20% or less, or 5% or more and 15% or less.
[0163] In one aspect, the transplant neural retina sheet of the present invention is a transplant neural retina that has been determined to be suitable for use as a transplant neural retina by the above-mentioned method for evaluating the quality of a transplant neural retina, and may be an isolated sheet-like transplant neural retina.
[0164] In one aspect, the transplantable neural retina sheet of the present invention is isolated from a cell aggregate containing a neural retina, and may be a transplantable neural retina sheet comprising a region near the center of the continuous epithelial tissue in the cell aggregate.
[0165] In one embodiment, the neural retina sheet for transplantation according to the present invention is isolated from a cell aggregate comprising at least a first epithelial tissue and a second epithelial tissue, the first epithelial tissue of the cell aggregate comprises a human neural retina, the second epithelial tissue has a continuity of the tangent slope of the surface different from the continuity of the tangent slope of the surface of the first epithelial tissue and comprises non-neural retinal cells, and the neural retina sheet for transplantation may comprise a region on the first epithelial tissue farthest from the second epithelial tissue, wherein the second epithelial tissue may be a tissue selected from the group consisting of eye-related tissue, telencephalospinal tissue, and tissue different from the neural retina of the first epithelial tissue.
[0166] In one embodiment, the neural retina sheet for transplantation according to the present invention may comprise a region near the center of the continuous epithelial tissue in the cell aggregate.
[0167] As described above, the neural retina sheet for transplantation can be isolated from a cell aggregate containing the neural retina, and can be obtained by the method for producing the neural retina sheet for transplantation described below.
[0168] In one embodiment, the major axis of the neural retina sheet for transplantation according to the present invention may be, for example, 300 μm to 3300 μm, preferably 600 μm to 2500 μm, and more preferably 1100 μm to 1700 μm.
[0169] In one embodiment, the minor axis of the neural retina sheet for transplantation according to the present invention may be, for example, 100 μm to 2000 μm, preferably 200 μm to 1500 μm, and more preferably 400 μm to 1100 μm.
[0170] In one embodiment, the height of the neural retina sheet for transplantation according to the present invention may be, for example, 50 μm to 1500 μm, preferably 100 μm to 1000 μm, and more preferably 200 μm to 700 μm.
[0171] In one embodiment, the volume of the neural retina sheet for transplantation according to the present invention is, for example, 0.001 mm 3~4.0mm 3 and preferably 0.01 mm 3 ~1.5mm 3 , more preferably 0.07 mm 3 ~0.57mm 3 It is.
[0172] The method for measuring the major axis, minor axis and height of the neural retina sheet for transplantation is not particularly limited, and may be measured from an image captured under a microscope. For example, a front image of a neural retina sheet for transplantation cut out from a cell aggregate is captured with the cut surface facing the objective lens side, and a lateral image is captured with the cut surface tilted so that it is perpendicular to the objective lens when viewed from the objective lens, and the image can be measured from the captured images. Here, the major axis means the longest line segment and its length among the line segments connecting two end points on the sheet cross section in the front image. The minor axis means the longest line segment and its length among the line segments connecting two end points on the sheet cross section in the front image and perpendicular to the major axis. The height means the longest line segment and its length among the line segments perpendicular to the sheet cross section, which have the intersection with the sheet cross section and the apex of the retina sheet as their end points. The volume of the sheet means the volume calculated according to the following formula, assuming that the graft is an ellipsoid cut in half so that the cross section passes through the major axis. Volume = 2 / 3 x Pi (π) x (major axis / 2) x (minor axis / 2) x height
[0173] Pharmaceutical compositions, methods of treatment, therapeutic agents and methods of production One aspect of the present invention includes a pharmaceutical composition comprising a neural retina sheet for transplantation. The pharmaceutical composition includes the neural retina sheet for transplantation of the present invention, and preferably further includes a medicamentously acceptable carrier. The pharmaceutical composition can be used to treat disorders of neural retinal cells or neural retina, or diseases caused by damage to the neural retina. Examples of diseases caused by disorders of neural retinal cells or neural retina include ophthalmic diseases such as retinal degeneration disease, macular degeneration, age-related macular degeneration, retinitis pigmentosa, glaucoma, corneal disease, retinal detachment, central serous chorioretinopathy, cone dystrophy, and cone-rod dystrophy. Examples of damaged states of the neural retina include states in which photoreceptor cells are degenerated and dead.
[0174] As a medicamentously acceptable carrier, a physiological aqueous solvent (such as physiological saline, a buffer solution, or a serum-free medium) can be used. If necessary, the pharmaceutical composition may contain preservatives, stabilizers, reducing agents, isotonicity agents, etc. that are commonly used in medicines containing tissues or cells to be transplanted in transplantation medicine.
[0175] As an embodiment of the present invention, a therapeutic agent for a disease caused by a neuroretinal disorder is provided, which comprises a neuroretinal sheet for transplantation obtained by the present invention. As another embodiment of the present invention, a method for treating a disease caused by a neuroretinal cell disorder or a neuroretinal injury, which comprises transplanting a neuroretinal sheet for transplantation obtained by the present invention into a subject in need of transplantation (e.g., under the retina of an eye with an ophthalmic disease), can be mentioned. The neuroretinal sheet for transplantation of the present invention can be used as a therapeutic agent for a disease caused by a neuroretinal injury, or to supplement the corresponding damaged site in a damaged state of the neuroretina. By transplanting the neuroretinal sheet for transplantation of the present invention into a patient who has a disease caused by a neuroretinal cell disorder or a neuroretinal injury or a patient in a damaged state of the neuroretina in need of transplantation, and supplementing the neuroretinal cell or the damaged neuroretina, the disease caused by a neuroretinal cell disorder or a neuroretinal injury state can be treated. As a transplantation method, for example, a method of transplanting a neuroretinal sheet for transplantation under the retina at the damaged site by incising the eyeball, etc. can be mentioned. Examples of the transplantation method include a method of injecting using a thin tube and a method of transplanting by pinching with tweezers. An example of the thin tube is a syringe needle.
[0176] One aspect of the present invention is a method for producing a neural retina sheet for transplantation obtained by the present invention. In one embodiment, the method for producing a neural retina sheet for transplantation includes evaluating a cell aggregate containing a neural retina having an epithelial structure derived from pluripotent stem cells using the above-mentioned method for evaluating a neural retina for transplantation, determining that the neural retina can be used as a neural retina for transplantation, and isolating the neural retina for transplantation that has been determined to be usable.
[0177] In another embodiment, a method for producing a transplant neural retina sheet includes extracting quality assessment samples, which are parts of a cell aggregate, from each of 2 to 800 cell aggregates containing a neural retina having an epithelial structure derived from pluripotent stem cells, evaluating the extracted 2 to 800 quality assessment samples by evaluating the neural retina for transplantation, selecting a neural retina for transplantation that is determined to be usable as a neural retina for transplantation, and isolating the selected neural retina for transplantation.
[0178] The cell aggregate is preferably a cell aggregate containing at least a first epithelial tissue and a second epithelial tissue obtained by inducing differentiation of pluripotent stem cells. The first epithelial tissue preferably contains human neural retina, and the second epithelial tissue preferably has a continuity of the tangent slope of the surface different from the continuity of the tangent slope of the surface of the first epithelial tissue, and contains non-neural retinal cells. The isolation of the neural retina for transplantation is preferably performed by isolating the neural retina for transplantation from the cell aggregate such that the neural retina for transplantation includes the region on the first epithelial tissue that is farthest from the second epithelial tissue. The isolation is performed by cutting out the neural retina by the above-mentioned method.
[0179] The quality evaluation method disclosed in the present invention uses the cell aggregate containing epithelial tissue as a raw material, a part of the epithelial tissue as a transplant sample, and another part of the epithelial tissue as a quality evaluation sample, which is particularly effective when each cell aggregate has a different morphology and structure, and can be applied to cell aggregates containing various epithelial tissues. EXAMPLES
[0180] The present invention will be described in detail below with reference to examples, but the present invention is not limited to these examples in any way.
[0181] Example 1: Preparation of cell aggregates containing neural retina Human iPS cells (DSP-SQ line, established by Sumitomo Dainippon Pharma Co., Ltd.) were established using commercially available Sendai virus vectors (four factors: Oct3 / 4, Sox2, KLF4, and c-Myc; CytoTune Kit, IDPharma) according to the protocol published by Thermo Fisher Scientific (iPS2.0 Sendai Reprogramming Kit, Publication Number MAN0009378, Revision 1.0) and the protocol published by Kyoto University (establishment and maintenance of human iPS cells in a feeder-free environment; CiRA_Ff-iPSC_protocol_JP_v140310, http: / / www.cira.kyoto-u.ac.jp / j / research / protocol.html) using StemFit medium (AK03; Ajinomoto Co., Inc.) and Laminin511-E8 (Nippi Co., Ltd.).
[0182] The human iPS cells (DSP-SQ line) were cultured in a feeder-free manner according to the method described in Scientific Reports, 4, 3594 (2014). StemFit medium (AK03N, Ajinomoto Co., Inc.) was used as the feeder-free medium, and Laminin511-E8 (Nippi Co., Ltd.) was used as the feeder-free scaffold.
[0183] As a specific maintenance culture procedure, first, subconfluent human iPS cells (DSP-SQ strain) were washed with PBS and dispersed into single cells using TrypLE Select (Life Technologies). The human iPS cells dispersed into single cells were then seeded onto a plastic culture dish coated with Laminin511-E8 and cultured feeder-free in StemFit medium in the presence of Y27632 (ROCK inhibitor, 10 μM). The plastic culture dish was a 6-well plate (Iwaki, for cell culture, culture area 9.4 cm). 2 ), the number of human iPS cells dispersed into the single cells was 1.0 × 10 4One day after seeding, the medium was replaced with StemFit medium not containing Y27632. Thereafter, the medium was replaced with StemFit medium not containing Y27632 once every 1 to 2 days. Thereafter, the cells were cultured for 5 days after seeding.
[0184] For differentiation induction, human iPS cells (DSP-SQ strain) were cultured in StemFit medium in a feeder-free manner until they reached subconfluency (approximately 30% of the culture area was covered with cells) 2 days before the subconfluency. The human iPS cells were cultured in the presence of SAG (300 nM) for 2 days in a feeder-free manner (preconditioning treatment).
[0185] The preconditioned human iPS cells were treated with TrypLE Select (Life Technologies) as a cell dispersion solution and further dispersed into single cells by pipetting. The dispersed human iPS cells were then placed in a non-cell-adhesive 96-well culture plate (PrimeSurface 96V bottom plate, Sumitomo Bakelite) at 1.3 × 10 cells per well. 4 The cells were suspended in 100 μl of serum-free medium and cultured at 37°C and 5% CO2. The serum-free medium (gfCDM+KSR) used was a 1:1 mixture of F-12 medium and IMDM medium, to which 10% KSR, 450 μM 1-monothioglycerol, and 1× chemically defined lipid concentrate were added. At the start of suspension culture (day 0 after the start of suspension culture), Y27632 (final concentration 20 μM) and SAG (final concentration 10 nM) were added to the serum-free medium. On the second day after the start of suspension culture, 50 μl of the above serum-free medium was added to the medium containing human recombinant BMP4 (R&D Co., Ltd.) without Y27632 or SAG, so that the final concentration of exogenous human recombinant BMP4 was 1.5 nM (55 ng / ml).
[0186] Four days later (six days after the start of suspension culture), the medium was replaced with the above serum-free medium that did not contain Y27632, SAG, or human recombinant BMP4. The medium replacement operation consisted of discarding 60 μl of the medium in the culture vessel and adding 90 μl of the above serum-free medium, making the total medium volume 180 μl. Thereafter, half of the medium was replaced with the above serum-free medium that did not contain Y27632, SAG, or human recombinant BMP4 once every 2 to 4 days. The half-medium replacement operation consisted of discarding half the volume of the medium in the culture vessel, i.e., 90 μl, and adding 90 μl of the above serum-free medium, making the total medium volume 180 μl.
[0187] The cell masses thus obtained, 13 days after the start of suspension culture, were cultured in serum-free medium (DMEM / F12 medium supplemented with 1% N2 supplement) containing CHIR99021 (3 μM) and SU5402 (5 μM) for 3 days, i.e., until the 16th day after the start of suspension culture.
[0188] The resulting cell aggregates on the 16th day after the start of suspension culture were cultured under 5% CO2 conditions using the serum medium shown in [1], [2], and [3] below, until the 75th day after the start of suspension culture. [1] From day 16 to day 40 after the start of suspension culture: DMEM / F12 medium supplemented with 10% fetal bovine serum, 1% N2 supplement, and 100 μM taurine (hereinafter referred to as medium A). [2] From the 40th to 60th day after the start of suspension culture: A medium and Neurobasal medium supplemented with 10% fetal bovine serum, 2% B27 supplement, 2mM glutamine, 60nM T3, and 100μM taurine (hereinafter referred to as B medium) were mixed in a 1:3 ratio. [3] After 60 days from the start of suspension culture: Medium B.
[0189] The cell masses were observed under an inverted microscope 75 days after the start of suspension culture to confirm their morphology, and it was found that neuroepithelial structures had formed.
[0190] The cell aggregates 75 days after the start of suspension culture were fixed with 4% paraformaldehyde and frozen sections were prepared. The frozen sections were immunostained for Chx10 (anti-Chx10 antibody, Exalpha, sheep), a neural retina marker, and Crx (anti-Crx antibody, Takara, rabbit), a photoreceptor precursor cell marker (Figure 1). Another frozen section was immunostained for Rx (anti-Rx antibody, Takara, guinea pig), a neural retina marker, and Recoverin (anti-Recoverin antibody, Proteintech, rabbit), a photoreceptor cell marker (Figure 2). Cell nuclei were stained with DAPI.
[0191] These stained sections were observed using a fluorescence microscope (Keyence) to obtain immunostained images. Photographs of the produced cells observed under a fluorescence microscope are shown in Figures 1 and 2. In Figures 1 and 2, the upper images are images taken with a low magnification lens, and the lower images are images taken with a high magnification lens.
[0192] From the DAPI staining images in Figures 1 and 2, it was found that the surface of the cell cluster had a densely packed nerve tissue, and that the nerve tissue formed a continuous epithelial structure. As a result of analyzing the image in Figure 1, it was found that a Crx-positive layer (photoreceptor layer) of about 2 to 5 cells was formed on the surface of the cell cluster, a Chx10-positive layer of about 5 to 20 cells was formed inside the Crx-positive layer, and a layer in which Crx-positive cells were sparsely present was formed further inside (Figure 1). It was found that the surface of this cell cluster was morphologically the apical surface. Furthermore, as a result of analyzing the image in Figure 2, it was found that a Recoverin-positive layer (photoreceptor layer) was formed in the nerve tissue, and an Rx-positive layer was also formed. From these results, it was found that the surface of the nerve tissue had a photoreceptor layer containing Crx-positive cells and Recoverin-positive cells, a retinal progenitor cell layer containing Chx10-positive cells was formed inside the photoreceptor layer, and a cell layer was also formed inside the retinal progenitor cells. In other words, this method makes it possible to produce a neural retina containing a photoreceptor layer and a retinal progenitor cell layer from human iPS cells, and it was found that this neural retina has a continuous epithelial structure.
[0193] <Example 2> Identification of non-target cells (non-neural retinal cells) and search for marker genes> Human iPS cells (QHJI-01-s04 line, obtained from the Center for iPS Cell Research and Application, Kyoto University) were differentiated into retina under various culture conditions. Specifically, human iPS cells maintained and cultured by the method described in Example 1 were cultured feeder-free until 2 days before subconfluency (approximately 30% of the culture area was covered with cells) or until 1 day before subconfluency (approximately 50% of the culture area was covered with cells). The human iPS cells 2 days before subconfluency were cultured feeder-free in the presence of SAG (300 nM) for 2 days, or the human iPS cells 1 day before subconfluency were cultured feeder-free in the presence of SAG (300 nM) and LDN (LDN193189, 100 nM) for 1 day (Precondition treatment).
[0194] The preconditioned human iPS cells were cultured in suspension as described in Example 1. The serum-free medium (gfCDM+KSR) was a 1:1 mixture of F-12 medium and IMDM medium supplemented with 10% or 5% KSR, 450 μM 1-monothioglycerol, and 1× chemically defined lipid concentrate. At the start of suspension culture (day 0 after the start of suspension culture), Y27632 (final concentration 20 μM) and IWR-1e (final concentration 3 μM), or Y27632 (final concentration 20 μM), IWR-1e (final concentration 3 μM), and SAG (30 nM) were added to the serum-free medium. On the third day after the initiation of suspension culture, 50 μl of the above-mentioned serum-free medium was added to the medium containing human recombinant BMP4 (manufactured by R&D) and IWR-1e, but not containing Y27632 or SAG, so that the final concentration of exogenous human recombinant BMP4 was 1.5 nM (55 ng / ml) and the final concentration of IWR-1e was 3 μM.
[0195] Three days later (six days after the start of suspension culture), the medium was replaced with the above serum-free medium containing IWR-1e but not containing Y27632, SAG, or human recombinant BMP4. For the medium replacement operation, 60 μl of the medium in the culture vessel was discarded, and 90 μl of the above serum-free medium was added, making the total medium volume 180 μl. 10 to 12 days after the start of suspension culture, a 67% medium replacement operation was performed twice using the above serum-free medium not containing IWR1-e, Y27632, SAG, or human recombinant BMP4 so that the concentration of exogenous IWR-1e was about 10% compared to before the medium replacement. Thereafter, half of the medium was replaced with the above serum-free medium not containing IWR1-e, Y27632, or human recombinant BMP4 once every 2 to 4 days. For half-medium exchange, half the volume of the medium in the culture vessel, ie, 90 μl, was discarded, and 90 μl of the above-mentioned serum-free medium was added, making the total medium volume 180 μl.
[0196] The cell masses thus obtained, 19 to 20 days after the start of suspension culture, were cultured in serum-free medium (DMEM / F12 medium supplemented with 1% N2 supplement) containing CHIR99021 (3 μM), a substance that acts on the Wnt signaling pathway, and SU5402 (5 μM), an FGF signaling pathway inhibitor, for 3 days, i.e., until the 22nd to 23rd day after the start of suspension culture.
[0197] Thereafter, the cells were cultured in the serum medium shown in [1], [2] and [3] described in Example 1, or in a medium (hereinafter referred to as Retina medium) containing 10% fetal bovine serum, 1% N2 supplement, 0.5 μM retinoic acid and 100 μM taurine added to DMEM / F12 medium under 5% CO2 conditions for 89 to 97 days after the start of suspension culture.
[0198] The cell aggregates obtained in this way on the 89th to 97th day after the start of the suspension culture were observed in bright field images (phase contrast images) using an inverted microscope (Nikon Corporation, ECLIPSE Ti). In particular, the observations were focused on the morphology of each individual cell and the characteristics of the adhesion state between the cells. In the cell aggregates, the area that had a continuous epithelial structure and was seen to be divided into two layers, the outer neuroblastic layer (including the photoreceptor layer and the neural retinal progenitor cell layer) and the inner neuroblastic layer, was determined to be the neural retina. In addition, tissues in which a continuous epithelial structure was not observed, or areas in which a continuous epithelial structure was observed but the outer neuroblastic layer and the inner neuroblastic layer could not be distinguished and appeared to be a single layer, were determined to be by-products (A, B, C, D, E, and F). Then, while observing with a stereomicroscope, the neural retina or by-products were cut out from the cell aggregates using fine tweezers and scissors under the stereomicroscope to prepare tissue pieces. The tissue pieces excised were a total of 33 samples: "Neural retina #1-9," "By-product A, #10-16," "By-product B, #17-20," "By-product C, #21, #22," "By-product D, #23, #24," "By-product E, #25-29," and "By-product F, #30-33."
[0199] Then, total RNA was extracted from the tissue slices using a spin column (RNeasy Micro kit, QIAGEN) according to the method described in the kit, and analyzed using a microarray (Human Genome U133 Plus2.0, Affymetrix) (Figure 3). Figure 3 shows a heat map, with gray corresponding to high gene expression and black corresponding to low gene expression (lighter colors correspond to higher gene expression).
[0200] As a result, it was found that the expression levels of the cone photoreceptor precursor marker RXRG, the rod photoreceptor precursor marker NRL, the photoreceptor marker Recoverin (also known as RCVRN), the photoreceptor precursor marker Crx, the neural retina marker Rax2, and the photoreceptor precursor marker Blimp1 (also known as PRDM1) were generally high in the nine tissue slices of "neural retina #1-9". In other words, it was confirmed that "neural retina #1-9" is retinal tissue containing neural retinal cells.
[0201] Furthermore, expression of HOX genes (HOXC5, HOXA5 and HOXB2) was observed in "neural retina #1-3". Retinoic acid was added to "neural retina #1-3" during the manufacturing process, and it is believed that the expression of the HOX genes is controlled by retinoic acid. However, as mentioned above, "neural retina #1-3" are good retinal tissues that contain neural retinal cells. Therefore, when retinoic acid is added to the manufacturing process, expression of the HOX genes (HOXC5, HOXA5 and HOXB2) is permitted.
[0202] "By-product A, #10-16" was analyzed. As a result, it was found that the expression level of neural retinal cell markers was generally low in by-product A. On the other hand, when searching for marker genes that are highly expressed in by-product A, it was found that GREM1, GPR17, ACVR1C, CDH6, Pax2, Pax8, GAD2 and SEMA5A were expressed. As a result of carefully examining the literature information on the markers (Baumer N, et al. Development. 2003 Jul; 130(13): 2903-15, Pfeffer PL, et al. Development. 1998 Aug; 125(16): 3063-74), it was found that by-product A is optic stalk. In other words, it was found that when neural retina is created from pluripotent stem cells in vitro, optic stalk may be produced as a by-product. Furthermore, it was found that GREM1, GPR17, ACVR1C, CDH6, Pax2, Pax8, GAD2 and SEMA5A are useful marker genes for distinguishing this optic stalk.
[0203] "By-product B, #17-20" was analyzed. As a result, it was found that by-product B generally had low expression levels of neural retinal cell markers. On the other hand, when searching for marker genes that were highly expressed in by-product B, it was found that Zic1, MAL, HNF1beta, FoxQ1, CLDN2, CLDN1, CRYAA, and CRYBA1 were expressed. After carefully examining the literature information on the markers, it was found that by-product B is the ciliary body, lens, and peripheral ciliary body (hereinafter referred to as the ciliary body and lens). In other words, it was found that the ciliary body and lens may be produced as by-products when neural retina is created from pluripotent stem cells in vitro. Furthermore, it was found that Zic1, MAL, HNF1beta, FoxQ1, CLDN2, CLDN1, CRYAA, and CRYBA1 are useful marker genes for distinguishing between the ciliary body and lens.
[0204] "By-products C, #21, #22" were analyzed. As a result, it was found that by-product C generally had low expression levels of neural retinal cell markers. On the other hand, when searching for marker genes that were highly expressed in by-product C, it was found that MITF, TTR, and BEST1 were expressed. After carefully examining the literature information on the markers, it was found that by-product C was retinal pigment epithelium (RPE). In other words, it was found that RPE may be generated as a by-product when neural retina is created from pluripotent stem cells in vitro. Furthermore, it was found that MITF, TTR, and BEST1 are useful marker genes for distinguishing this RPE.
[0205] "By-products D, #23, #24" were analyzed. As a result, it was found that by-product D generally had low expression levels of neural retinal cell markers. On the other hand, when searching for marker genes that are highly expressed in by-product D, it was found that HOXD4, HOXD3, HOXD1, HOXC5, HOXA5, and HOXB2 were expressed. After carefully examining the literature information on the markers, it was found that by-product D is spinal cord tissue. In other words, it was found that spinal cord tissue may be generated as a by-product when neural retina is created from pluripotent stem cells in vitro. Furthermore, it was found that HOXD4, HOXD3, HOXD1, HOXC5, HOXA5, and HOXB2 are useful marker genes for distinguishing this spinal cord tissue.
[0206] "By-product E, #25-29" was analyzed. As a result, it was found that by-product E generally had low expression levels of neural retinal cell markers. On the other hand, when searching for marker genes highly expressed in by-product E, it was found that Nkx2.1, OTP, FGFR2, EFNA5, and GAD1 were expressed. After carefully examining the literature information on the markers, it was found that by-product E is the diencephalon, midbrain, and hypothalamus (hereinafter referred to as the diencephalon and midbrain). In other words, it was found that the diencephalon and midbrain may be generated as by-products when neural retina is created from pluripotent stem cells in vitro. Furthermore, it was found that Nkx2.1, OTP, FGFR2, EFNA5, and GAD1 are useful marker genes for distinguishing the diencephalon and midbrain.
[0207] "By-product F, #30-33" was analyzed. As a result, it was found that by-product F generally had low expression levels of neural retinal cell markers. On the other hand, when searching for marker genes that are highly expressed in by-product F, it was found that DLX2, DLX1, DLX5, FOXG1, EMX2, GPR177 (Wls), and AQP4 were expressed. After examining the literature information on the markers, it was found that by-product F is the telencephalon because DLX2, DLX1, DLX5, FOXG1, and EMX2 were expressed. It was found that GPR177 and AQP4 are also useful as by-product markers. In other words, it was found that the telencephalon may be generated as a by-product when neural retina is created from pluripotent stem cells in vitro. Furthermore, it was found that DLX2, DLX1, DLX5, FOXG1, and EMX2 are useful marker genes for distinguishing this telencephalon.
[0208] From the above results, it was found that the expression levels of marker genes for neural retinal cells were low in the by-products, and the expression levels of genes known to be expressed in the optic stalk, ciliary body, lens, RPE, spinal cord, diencephalon, midbrain, and telencephalon tissues were high. From the above, it was found that the optic stalk, ciliary body, lens, RPE, spinal cord, diencephalon, midbrain, and telencephalon can be by-produced during the process of differentiation into a three-dimensional retina. In addition, it was found that the genes shown in Table 11 are markers that can detect each tissue.
[0209] [Table 11]
[0210] Example 3: Development of a method for evaluating grafts The three-dimensional retina created from human iPS cells consists of a neural retina with a neuroepithelial structure that has a continuous cellular composition and distribution. This neural retina with a neuroepithelial structure has a layered structure consisting of a photoreceptor layer and an inner layer, and has a characteristic appearance and morphology (Figure 1).
[0211] Human three-dimensional retinas are about 1 to 2 mm in size and each one has a different shape. In addition, due to the characteristics of the manufacturing method using self-organizing culture, it was found that although the neural retina used for transplantation is the main product, non-neural retina, eye-related tissues (RPE, ciliary body, etc.) and cerebrospinal tissues (telencephalon, spinal cord, etc.) are by-produced (Example 2). Therefore, it was decided to obtain a retinal piece (graft, Cap, cap) by cutting out the center of the neural retina that does not contain non-neural retina (Figures 4 and 5). It is considered that it is desirable to perform a total test for the quality evaluation of the composition and purity of the retinal piece, but destructive testing of all the retinal pieces is not possible. Therefore, it was decided to use the peripheral part of the retinal piece (Cap) as a quality evaluation sample (Ring, ring). Then, it was decided to analyze all the Rings (preferably by quantitative PCR), and it was considered to use only the Caps corresponding to the Rings that meet the standards as neural retina for transplantation.
[0212] 4 and 5 are conceptual diagrams of typical cell aggregates. The area where a neuroepithelial structure (preferably a continuous epithelial structure) specific to the neural retina, in which the photoreceptor layer and the inner layer appear to be separated into two layers, is observed is designated as a graft (cap), the area around the cap where a neuroepithelial structure (preferably a continuous epithelial structure) similar to that of the cap is observed is designated as a quality evaluation sample (ring), and the area other than the cap and ring is called a root.
[0213] Below, we investigated the usefulness of the technique for isolating the cap and ring from neuroepithelial structures contained in a single cell aggregate.
[0214] Example 4: Shape of the graft (cap) Grafts (caps) were prepared by the following method (FIG. 6). First, bright-field images (phase contrast images) of cell aggregates prepared from human iPS cells (DSP-SQ strain) on the 99th day after the start of suspension culture according to the method described in Example 1 were captured with an inverted microscope (Olympus). After confirming that neural retina was present on the cell aggregates, the cell aggregates were transferred under a stereomicroscope, and neural retina of various sizes were cut out as grafts using the method described in Example 2. In addition, the effect of the size of the graft on the transplantation operation using a transplantation device was examined.
[0215] The cut graft was photographed with a stereomicroscope in a front image with the cut surface facing the objective lens, and in a side image with the cut surface tilted so that it was perpendicular to the objective lens. The long and short diameters and height of the graft were then measured from the photographed images. In the measurement, the long diameter refers to the longest line segment and its length among the line segments connecting two end points on the cross section of the retinal sheet in the front image. The short diameter refers to the longest line segment and its length among the line segments connecting two end points on the cross section of the retinal sheet in the front image and perpendicular to the long diameter. The height refers to the longest line segment and its length among the line segments perpendicular to the cross section of the retinal sheet in the side image, whose end points are the intersection point with the cross section of the retinal sheet and the surface of the retinal sheet. Furthermore, the volume of the graft was calculated according to the following formula, approximating the graft as an ellipsoid divided in half so that the cross section passes through the long diameter. Volume = 2 / 3 x pi x (major axis / 2) x (minor axis / 2) x height
[0216] As a result, it was found that the placement of the graft in the transplant device, the stability of the graft in the transplant device, and the ejection of the graft from the transplant device are affected by the size of the graft. It was also suggested that the minor axis is a particularly useful parameter. The major axis, minor axis, height, and volume were calculated for 11 grafts that were successfully transplanted using the transplant device. The average, maximum, and minimum values for each parameter were calculated and are summarized in Table 12. From these results, it was found that the grafts (caps) had a major axis of at least 0.8 to 1.7 mm, a minor axis of 0.4 to 1.1 mm, a height of 0.2 to 0.7 mm, and an apparent volume of 0.07 to 0.57 mm. 3 It was found to be to an extent. [Table 12]
[0217] Example 5: Cellular composition of the graft (cap) A graft (cap) was prepared by the following method (number: 18001MF, d89, H5). First, a graft (cap) was isolated from a cell aggregate prepared from human iPS cells (DSP-SQ strain) on the 89th day after the start of suspension culture according to the method described in Example 1, by the methods described in Examples 2 and 3.
[0218] The grafts were fixed with 4% paraformaldehyde and frozen sections were prepared. The frozen sections were immunostained for Chx10 (anti-Chx10 antibody, Exalpha, sheep), a neural retina marker, and Crx (anti-Crx antibody, Takara, rabbit), a photoreceptor precursor cell marker (Figure 7). Another frozen section was immunostained for Rx (anti-Rx antibody, Takara, guinea pig), a neural retina marker, and Recoverin (anti-Recoverin antibody, Proteintech, rabbit), a photoreceptor cell marker (Figure 7). Cell nuclei were stained with DAPI. These stained sections were observed using a confocal laser microscope (Olympus), and immunostained images were obtained.
[0219] From the staining image, it was found that the surface of the graft (cap) (left side of the figure) had formed a neural tissue densely packed with cells, and that the neural tissue had formed a neuroepithelial structure (particularly a continuous epithelial structure) (Figure 7). Furthermore, it was found that a Crx-positive layer (photoreceptor layer, Figure 7) with a thickness of about 2 to 10 cells was formed on the surface of the cell mass in this neural tissue, a Chx10-positive layer with a thickness of about 5 to 20 cells was formed inside the Crx-positive layer, and a layer containing Crx-positive cells was formed further inside (Figure 7). It was found that the surface of this graft (cap) was morphologically the apical surface. Furthermore, it was found that a Recoverin-positive layer (photoreceptor layer, Figure 7 arrow) was formed in this neural tissue, and an Rx-positive layer was also formed. From these results, it was found that the photoreceptor layer containing Crx-positive cells and Recoverin-positive cells was formed on the surface of this neural tissue, a retinal progenitor cell layer containing Chx10-positive cells was formed inside the photoreceptor layer, and a cell layer was also formed inside the retinal progenitor cells. In other words, the graft (cap) was able to produce a neural retina including a photoreceptor layer and a retinal progenitor cell layer, and it was found that this neural retina has a continuous epithelial structure.
[0220] <Example 6 Verification of the equivalence of the cap and the ring> In order to compare gene expression of the cap and the ring, the following method was used. First, according to the method described in Example 1, a cell aggregate was prepared from human iPS cells (DSP-SQ strain) on the 99th day after the start of floating culture, and was designated as lot 1. Furthermore, according to the method described in Example 1, a cell aggregate was prepared from human iPS cells (DSP-SQ strain) on the 82nd day after the start of floating culture, and was designated as lot 2. For these two lots, the main product, neural retina, and by-products were determined using a microscope by the methods described in Examples 2 and 3, and the neural retina cap and the by-product cap were isolated, respectively. The ring was isolated by cutting out under a stereomicroscope using fine tweezers and scissors, similar to the graft. Total RNA was extracted from the cap and ring isolated from the neural retina and by-product by the method described in Example 2. The concentration of total RNA was measured using a measuring device (Nanodrop, Thermo Scientific), and then reverse transcribed into cDNA using reverse transcriptase and a primer (Reverse Transcription Master Mix Kit, Fluidigm). cDNA was subjected to multiplex-PCR reaction (Pre-Run) using all probes used for verification, using a PCR device (Veriti 96well thermal cycler, Applied Biosystems). After that, the pre-run reaction solution was injected into a multi-well with a flow path (96.96 Dynamic Array IFC, Fluidigm) using an IFC controller HX (Fluidigm), and the expression levels of marker genes for neural retina and by-products other than neural retina were measured by real-time PCR using a multi-sample real-time PCR system (Biomark HD, Fluidigm). The PCR probes used for verification are shown in Table 13.
[0221] [Table 13]
[0222] The results are shown in the heat map in FIG. 8. The gene expression level was evaluated by the ΔCt value calculated from the difference between the Ct value of the gene of interest and the Ct value of GAPDH, a gene used as an internal standard. The lower the ΔCt value, the higher the gene expression level, and the higher the ΔCt value, the lower the gene expression level. Gray indicates a high gene expression level, and black indicates a low gene expression level (a lighter color indicates a higher gene expression level). When the gene expression of each cap and ring was examined, the neural retina marker gene group was expressed in the cap and ring isolated from the neural retina in both Lot 1 and Lot 2. On the other hand, when the gene expression of the cap and ring isolated from the by-product was examined, in both lots, the expression level of the neural retina marker gene group was low, and the expression level of the by-product marker gene group was high, contrary to the neural retina. From this, it was confirmed that the marker gene group found in Example 2 could be detected by distinguishing between the neural retina and the by-product. Furthermore, when we compared gene expression in caps and rings isolated from the same cell aggregates, we found that the expression levels of neural retinal marker genes and by-product marker genes were equivalent in caps and rings isolated from all neural retina and by-products.
[0223] These results demonstrate that if the ring is neural retina, then the cap is also neural retina, and that gene expression is equivalent in the cap and ring.
[0224] Example 7: Verification of the equivalence of the cap and ring in various pluripotent stem cell lines To examine whether gene expression in the cap and ring is comparable in cell aggregates differentiated from various pluripotent stem cells, the following was performed.
[0225] First, Crx::Venus knock-in human ES cells (derived from KhES-1; Nakano, T. et al. Cell Stem Cell 2012, 10(6), 771-785; obtained from Kyoto University, established and used at RIKEN CDB), human iPS cells (QHJI-01-s04 strain), and human iPS cells (DSP-SQ strain) were differentiated into retinas by the method described in Example 1. Then, neural retina and by-product caps and rings were excised from cell aggregates 70 days or more after the start of floating culture by the method described in Example 6. Then, total RNA was extracted by the method described in Example 6. The concentration of total RNA was measured using a measuring device (Nanodrop, Thermo Scientific), and then reverse transcribed into cDNA using reverse transcriptase and primer (Reverse Transcription Master Mix Kit, Fluidigm). cDNA was subjected to multiplex-PCR reaction (Pre-Run) using all probes used for verification, using a PCR device (Veriti 96 well thermal cycler, Applied Biosystems). After that, the pre-run reaction solution was injected into a multi-well with a flow path (96.96 Dynamic Array IFC, Fluidigm) using an IFC controller HX (Fluidigm), and the expression levels of marker genes for neural retina and by-products other than neural retina were measured by real-time PCR using a multi-sample real-time PCR system (Biomark HD, Fluidigm). The PCR probes shown in Table 3 of Example 6 were used for verification.
[0226] The results are shown in the heat map of FIG. 9. The heat map was prepared according to the method described in Example 6. When gene expression in the caps and rings was examined, it was found that in caps and rings derived from any cell line, the expression level of neural retina marker genes was high in those isolated from the neural retina, and the expression level of by-product marker genes was low. On the other hand, in caps and rings isolated from by-products, the expression level of by-product marker genes was high, and the expression level of neural retina marker genes was low. In addition, when gene expression of caps and rings isolated from the same cell aggregate was compared, it was found that the marker genes of neural retina and by-products were expressed to the same extent in caps and rings isolated from any cell line.
[0227] These results demonstrated that, in cell aggregates derived from any pluripotent stem cell line, if the ring is neural retina, then the cap is also neural retina. Furthermore, it was demonstrated that gene expression is equivalent in the cap and ring. In other words, it was found that whether a cap of the size shown in Table 2 is excised or a ring is excised from the remaining part of the cell aggregate, a ring with the same gene expression as the cap can be excised.
[0228] <Example 8: Results of transplantation of grafts> In Examples 6 and 7, it was found that the gene expression of the cap and the ring was equivalent. In addition, if the ring is a neural retina, it was confirmed that the cap is also a neural retina. Therefore, a method was devised in which the gene expression of the ring was analyzed before transplantation to confirm that the ring is a neural retina, and a cap corresponding to the ring was transplanted. In order to demonstrate the usefulness of this method, the gene expression of the ring was analyzed, and then the corresponding cap was transplanted into a nude rat with retinal degeneration, and the engraftment after transplantation was evaluated.
[0229] First, cell aggregates were prepared from human iPS cells (DSP-SQ strain) according to the method described in Example 1. Then, caps and rings were isolated from cell aggregates on or after 75 days from the start of suspension culture according to the method described in Example 6. The isolated caps were stored using a commercially available preservation solution while performing genetic analysis of the rings. Gene expression analysis was performed on the isolated rings by real-time PCR using Biomark HD (Fluidigm) according to the method described in Example 6. From the results of gene expression analysis, rings that expressed neural retina marker genes and did not express by-product marker genes were selected, and caps corresponding to these rings were selected as grafts. The grafts were washed with a buffer solution (Thermo Fisher Scientific) and then transplanted under the retina of retinal degeneration nude rats (photoreceptor degeneration model, SD-Foxn1 Tg(S334ter)3LavRrrc nude rats) using an injector described in a known literature (Shirai et al. PNAS 113, E81-E90).
[0230] Ocular tissues aged 230 to 240 days after the start of suspension culture were fixed with paraformaldehyde (PFA) and sucrose substituted. The fixed ocular tissues were frozen into sections using a cryostat. These frozen sections were immunostained for human nuclei (anti-HuNu antibody, Millipore, mouse, or anti-HNA antibody), a marker for photoreceptor cells, Recoverin (anti-Recoverin antibody, Proteintech, rabbit), and PKCα, a marker for bipolar cells (anti-PKCα antibody, R&D systems, goat).
[0231] Table 14 shows the results of the quality evaluation of the grafts and the transplantation results by the gene expression analysis of the ring. The ΔCt value was calculated using the method described in Example 6. The gene expression analysis of the ring was deemed to have passed the quality evaluation test (ring-PCR test) if the ΔCt value of Recoverin, one of the neural retina marker genes, was 10 or less, and the ΔCt values of the by-product marker genes FOXG1, HOXB2, ZIC1, and OCT3 / 4 were 5 or more. Regarding the transplantation results, if human nucleus-positive and Recoverin-positive photoreceptors were detected under the retina, the engraftment was evaluated as good. In addition, if the transplant site was not significantly thickened beyond the appropriate engraftment size, it was determined that no hypertrophy was detected.
[0232] A representative image of engraftment is shown in Figure 10. When the post-transplant engraftment images of 14 eyes that passed the quality evaluation test before transplantation were evaluated, Recoverin-positive photoreceptors were detected in all 14 eyes, indicating good engraftment. These cells were HuNu-positive, indicating that the Recoverin-positive photoreceptors were derived from the transplanted cap. Furthermore, no hypertrophy was detected in any of the 14 eyes.
[0233] These results demonstrate that by examining the expression levels of marker genes for the neural retina and its by-products prior to transplantation through gene expression analysis of the ring, it is possible to select grafts that will engraft well under the retina, i.e., grafts in which photoreceptor cells will engraft and not undergo hypertrophy.
[0234] [Table 14]
[0235] Example 9: Results of transplantation of grafts In Example 8, Biomark HD (Fluidigm) was used for gene expression analysis of the ring. Biomark HD is a machine originally designed for single cell analysis, and its use in Example 8 is not common. Therefore, gene expression of the ring was analyzed using a commonly used real-time PCR device, and it was verified whether it was possible to select a graft that would take root well under the retina, as in the case of using Biomark HD.
[0236] Human iPS cells (DSP-L line, established by Sumitomo Dainippon Pharma) were established using commercially available Sendai virus vectors (four factors: Oct3 / 4, Sox2, KLF4, and c-Myc; CytoTune Kit, IDPharma) according to the protocol published by Thermo Fisher Scientific (iPS 2.0 Sendai Reprogramming Kit, Publication Number MAN0009378, Revision 1.0) and the protocol published by Kyoto University (establishment and maintenance of human iPS cells in a feeder-free environment; CiRA_Ff-iPSC_protocol_JP_v140310, http: / / www.cira.kyoto-u.ac.jp / j / research / protocol.html) using StemFit medium (AK03; Ajinomoto Co.) and Laminin511-E8 (Nippi Co.).
[0237] First, cell aggregates were prepared from human iPS cells (DSP-L strain) according to the method described in Example 1. Then, caps and rings were isolated from the cell aggregates on the 86th day after the start of suspension culture according to the method described in Example 6. The isolated caps were preserved using a commercially available preservation solution while genetic analysis of the rings was performed. Gene expression analysis of the isolated rings was performed as follows.
[0238] First, total RNA was extracted by the method described in Example 2. The concentration of total RNA was measured using a measuring device (Nanodrop, Thermo Scientific), and then reverse transcribed into cDNA using reverse transcriptase (QuantiTect Reverse Transcription Kit (QIAGEN) and primer (RT primer mix, QIAGEN). Then, the expression levels of marker genes of neural retina and by-products other than retina were measured by real-time PCR using a real-time PCR enzyme (TaqMan Fast Advanced Master Mix, Applied Biosystems) and a StepOnePlus real-time PCR system (Applied Biosystems). The results are shown in FIG. 11. A sample containing cDNA of undifferentiated iPS cells and cDNA of stereoscopic retina was used as a positive control sample. The positive control sample was serially diluted to prepare a standard curve sample, and a standard curve was drawn. Gapdh was used as an internal standard to normalize gene expression.
[0239] As a result of PCR analysis, it was found that Sample 1 and Sample 2 had high expression levels of neural retina markers Chx10, Rx, Crx and Recoverin, and low expression levels of by-product marker genes Oct3 / 4, FoxG1, Aqp1, Nkx2.1, Dlx6, CDH6, Emx2, Zic1, HoxA5, Pax2 and Pax8. Rings expressing neural retina marker genes and not expressing by-product marker genes were selected, and the caps corresponding to the rings were transplanted under the retina of nude rats with retinal degeneration according to the method described in Example 8.
[0240] Ocular tissues aged 230 to 240 days after the start of suspension culture were fixed with paraformaldehyde (PFA) and sucrose substituted. The fixed ocular tissues were frozen into sections using a cryostat. These frozen sections were immunostained for human nuclei (anti-HuNu antibody, Millipore, mouse), Recoverin, a marker for photoreceptor cells (anti-Recoverin antibody, Proteintech, rabbit), and SCGN, a marker for bipolar cells (anti-SCGN antibody, BioVendor, sheep).
[0241] The engraftment image of the rat eye transplanted with the cap corresponding to the ring is shown in FIG. 11. When the engraftment image after transplantation was evaluated, Recoverin-positive photoreceptors were observed, indicating good engraftment. These cells were HuNu-positive, indicating that the Recoverin-positive photoreceptors were derived from the transplanted cap. Furthermore, no hypertrophy was observed.
[0242] These results indicate that even if gene expression in the ring is analyzed using a commonly used real-time PCR system, it is possible to select grafts that will be successfully engrafted under the retina by examining the expression levels of marker genes for the neural retina and by-products before transplantation. Therefore, it was demonstrated that the analysis of multiple genes is possible using a multi-sample real-time PCR system.
[0243] Example 10: Results of ring implantation. In Examples 8 and 9, it was found that when the cap prepared by the above-mentioned method was transplanted under the retina of a nude rat with retinal degeneration, photoreceptor cells were engrafted. In order to verify the equivalence of the ring and the cap, a study was conducted in which a ring was similarly transplanted under the retina.
[0244] Crx::Venus knock-in human ES cells (derived from KhES-1; Nakano, T. et al. Cell Stem Cell 2012, 10(6), 771-785; obtained from Kyoto University, established at RIKEN CDB and used) were differentiated into retinas by the method described in Example 1. Then, neural retina and by-product cap and ring were excised from cell aggregates on the 74th day after the start of floating culture by the method described in Example 6 (Figure 12). Then, the ring was transplanted under the retina of a nude rat with retinal degeneration (SD-Foxn1 Tg(S334ter)3LavRrrc nude rat), a photoreceptor degeneration model, using a syringe as described in a publicly known literature (Shirai et al. PNAS 113, E81-E90).
[0245] The nude rats with retinal degeneration were allowed to grow for one year after the transplantation. The ocular tissues with the rings transplanted were then excised, fixed in paraformaldehyde (PFA) and sucrose-substituted. Frozen sections were prepared from the fixed ocular tissues using a cryostat. These frozen sections were immunostained for the human cytoplasmic marker Stem121 (anti-Stem121 antibody, Cellartis, mouse) or Recoverin (anti-Recoverin antibody, Proteintech, rabbit), a marker for photoreceptor cells.
[0246] Figure 12 shows a bright field image taken immediately after cutting out the ring used for transplantation, and the results of immunostaining a section prepared from ocular tissue extracted from a rat that had been grown for one year after the ring was transplanted. When the ring shown on the left in Figure 12 was transplanted under the retina of a nude rat with retinal degeneration, the immunostaining results shown on the right in Figure 12 were obtained. The immunostaining results showed that Stem121-positive human cells had taken root. It was also found that Recoverin-positive photoreceptor cells had taken root.
[0247] These results indicate that photoreceptor cells can be engrafted when transplanted into the ring, just like in the cap. Furthermore, these results suggest that similar transplant outcomes can be obtained for neural retina, whether transplanted into the cap or the ring.
[0248] <Example 11: Verification of equivalence of cap and ring> In Examples 6 and 7, it was demonstrated by PCR that the gene expression of the cap and the ring are equivalent at the RNA level. It was also demonstrated that it is possible to verify whether the cap is the neural retina or a by-product by analyzing the gene expression of the ring by PCR. Next, it was examined whether it is possible to verify whether the cap is the neural retina or a by-product by analyzing the gene expression of the ring by immunostaining.
[0249] First, human iPS cells (DSP-SQ strain) were differentiated into retinas by the method described in Example 1. Then, the neural retina cap and ring were isolated from the cell aggregates 120 days after the start of floating culture by the method described in Example 6. The cap and ring were then washed, fixed with 4% paraformaldehyde (PFA fixation), and sucrose substituted. The fixed cap and ring were subjected to frozen sectioning using a cryostat. These frozen sections were immunostained for DAPI, which stains nuclei, Crx, a marker for photoreceptor precursor cells (anti-Crx antibody, Takara, rabbit), Chx10, a marker for neural retina (anti-Chx10 antibody, Exalpha, sheep), NRL, a marker for rod photoreceptor precursor cells (anti-NRL antibody, Bio-Techne, goat), FOXG1, a marker for telencephalon (anti-FOXG1 antibody, Takara Bio, rabbit), PAX2, a marker for optic stalk (anti-PAX2 antibody, Thermo Fisher Scientific, rabbit), and NANOG, a marker for undifferentiated pluripotent stem cells (anti-NANOG antibody, Merck, mouse).
[0250] The results of immunostaining are shown in FIG. 13. For the cap and ring excised from the same cell aggregate, the results of immunostaining of the ring are shown in the upper row, and the results of immunostaining of the cap are shown in the lower row. From these results, it was found that Crx-positive photoreceptor precursor cells, Chx10-positive neural retina, and NRL-positive rod photoreceptor precursor cells were continuously expressed in layers in both the cap and the ring. In addition, FOXG1-positive telencephalon, PAX2-positive Optic Stalk, and NANOG-positive pluripotent stem cells were not detected in either the cap or the ring. Furthermore, when the stained images of Crx, Chx10, and NRL were compared, it was found that these neural retina markers showed almost the same distribution in the cap and the ring.
[0251] These results demonstrated that the cap and the ring are equivalent not only by gene expression analysis but also by immunohistochemistry. These results also demonstrated that by analyzing the gene expression of the ring by immunohistochemistry, it is possible to verify whether the cap is the neural retina or a by-product.
[0252] Example 12: Verification of the equivalence of the cap and ring in non-neural retina In Examples 6 and 7, it was found that gene expression was equivalent in the neural retina and the by-product cap and ring. Therefore, we decided to conduct a detailed analysis to determine whether gene expression was equivalent in caps and rings isolated from tissues other than the retina.
[0253] First, human iPS cells (QHJI-01-s04 strain) and human iPS cells (DSP-SQ strain) were differentiated into retinas by the method described in Example 1. Then, cell aggregates 80 days or more after the start of floating culture were examined under a microscope, and the presence of an epithelial structure was observed. The neural retina and by-product caps and rings were excised from the cell aggregates 80 days or more after the start of floating culture by the method described in Example 6. Then, RNA was extracted by the method described in Example 6, and the expression levels of marker genes for neural retina and by-products other than retina were measured by real-time PCR using Biomark HD (Fluidigm).
[0254] The results are shown in the heat map in FIG. 14. The heat map was prepared according to the method described in Example 6. When gene expression in the caps and rings was examined, it was confirmed that the neural retina marker gene was expressed in the caps and rings excised from the neural retina, and the marker gene of the by-product was not expressed. On the other hand, when gene expression in the caps and rings excised from the by-products was examined, caps and rings highly expressing FOXG1, which is one of the telencephalon markers, caps and rings highly expressing HOXB2 and HOXA5, which are spinal cord markers, caps and rings highly expressing MITF, which is one of the RPE markers, and caps and rings highly expressing PAX2, which is one of the Optic Stalk markers, were observed. Therefore, these by-products were classified into telencephalon tissue, spinal cord tissue, RPE, and Stalk, respectively, based on the marker genes that were highly expressed. When gene expression in the caps and rings isolated from these by-products was examined, the caps and rings showed equivalent gene expression in all by-products.
[0255] These results indicate that gene expression is equivalent in the caps and rings isolated not only from the neural retina, but also from the telencephalon, spinal cord, RPE, and optic stalk. These results also indicate that by examining gene expression in rings isolated from non-neural retina tissues such as the telencephalon, spinal cord, RPE, and optic stalk, it is possible to determine whether the caps are the same tissue.
[0256] <Example 13> Proportion of photoreceptor precursor cells and neural retinal precursor cells constituting neural retinal sheet for transplantation The proportion of photoreceptor precursor cells and neural retinal progenitor cells among the constituent cells of the neural retinal sheet for transplantation, which was prepared from cell aggregates differentiated from pluripotent stem cells, was analyzed and quantified using immunohistochemistry (IHC), a type of immunostaining method.
[0257] Human iPS cells (DSP-SQ strain) were differentiated into retinas by the method described in Example 1. Then, caps and rings were isolated from the cell aggregates on the 84th, 92nd, and 93rd days after the start of floating culture by the method described in Example 6. Gene expression analysis of the isolated rings was performed by the method described in Example 8. By the method described in Example 8, a ring that expressed a neural retina marker gene and did not express a by-product marker gene was selected, and the cap corresponding to this ring was used as a neural retina sheet for transplantation. In this way, one neural retina sheet for transplantation was prepared from the cell aggregate on the 84th day after the start of floating culture, two neural retina sheets for transplantation were prepared from the cell aggregate on the 92nd day after the start of floating culture, and one neural retina sheet for transplantation was prepared from the cell aggregate on the 93rd day after the start of floating culture. That is, a total of four neural retina sheets for transplantation were prepared.
[0258] The obtained neural retina sheet for transplantation was cultured in B medium for 7 days for analysis. The cultured neural retina sheet for transplantation was fixed with 4% paraformaldehyde to prepare frozen sections. The frozen sections were immunostained for Chx10 (anti-Chx10 antibody, Exalpha, sheep), which is a neural retina progenitor cell marker, and Crx (anti-Crx antibody, Takara, rabbit), which is a photoreceptor progenitor cell marker. Another frozen section was immunostained for Rx (anti-Rx antibody, Takara, guinea pig), which is a neural retina marker, and Recoverin (anti-Recoverin antibody, Proteintech, rabbit), which is a photoreceptor cell marker. The cell nuclei were stained with DAPI. These stained sections were observed using a fluorescence microscope (Keyence) to obtain immunostained images. An example (D3) is shown in FIG. 15.
[0259] The immunostained images were analyzed using ImageJ (version 1.52a, manufactured by NIH), and the number of DAPI-positive cells, the number of DAPI-positive and Chx10-positive cells, and the number of DAPI-positive and Crx-positive cells were analyzed for each of the four neural retina sheets for transplantation. Similarly, the immunostained images were analyzed, and the number of DAPI-positive cells, and the number of DAPI-positive and Rx-positive cells were analyzed. From these values, the percentage of Chx10-positive cells, the percentage of Crx-positive cells, and the percentage of Rx-positive cells were calculated. The results obtained are shown in Table 15. [Table 15]
[0260] From the above results, it was found that the percentage of Chx10-positive cells contained in the neural retina sheet for transplantation was approximately 23-45%, the percentage of Crx-positive cells was approximately 30-56%, and the percentage of Rx-positive cells was approximately 40-54%.
[0261] In other words, it was suggested that the neural retinal sheet for transplantation contains approximately 34% (23-45%) Chx10-positive neural retinal progenitor cells, approximately 40% (30-56%) Crx-positive photoreceptor progenitor cells, and approximately 47% (40-54%) Rx-positive cells.
[0262] <Example 14> Proportion of photoreceptor precursor cells and neural retinal precursor cells constituting neural retinal sheet for transplantation The composition of the constituent cells in neural retina sheets for transplantation, which were prepared from cell aggregates differentiated from various pluripotent stem cells, was investigated using flow cytometry (also known as FACS), an immunostaining method.
[0263] Human iPS cells (QHJI-01-s04 strain) were differentiated into retinas by the method described in Example 1. Then, caps and rings were isolated from the cell aggregates on the 88th day after the start of floating culture by the method described in Example 6. The caps were used as neural retina sheets for transplantation. The neural retina sheets for transplantation were stored at low temperature at 17°C for 2 days. Five of the obtained neural retina sheets for transplantation were combined into one sample, washed with PBS, and enzyme-treated with a nerve cell dispersion solution (manufactured by WAKO, containing papain) at 37°C for about 30 minutes, and dispersed into single cells by pipetting to obtain a single cell suspension. The obtained single cell suspension was fixed with a fixative solution (manufactured by BD, CytoFix) to obtain a sample for FACS. The sample for FACS was blocked and permeabilized (holes in the cell membrane) using a serum-containing Perm / Wash solution (manufactured by BD). Immunostaining was performed using the following fluorescently labeled antibodies: anti-Chx10 antibody (Santa Cruz), anti-Pax6 antibody (BD), and anti-Crx antibody (Santa Cruz). Analysis was performed by flow cytometry using an analyzer (BD).
[0264] As a result, the Chx10-positive and Pax6-positive fraction (neural retinal progenitor cell fraction) was 11.5%, the Chx10-positive and Pax6-negative fraction (bipolar cell-biased progenitor cell fraction) was 23.4%, the Chx10-negative and Pax6-positive fraction (ganglion cell and amacrine cell fraction) was 10.7%, and the Crx-positive cell fraction (photoreceptor progenitor cell fraction) was 17.4%.
[0265] Furthermore, human iPS cells (DSP-SQ strain) were differentiated into retinas by the method described in Example 1. Thereafter, 11 cell aggregates were prepared on the 88th day after the start of floating culture, and 11 caps and rings were isolated from each cell aggregate by the method described in Example 6. The 11 caps were combined into one cap sample. Similarly, the 11 rings were combined into one ring sample. The cap sample and the ring sample were each washed with PBS, and subjected to enzyme treatment using a nerve cell dispersion liquid (manufactured by WAKO, containing papain) at 37°C for about 30 minutes to obtain single cell suspensions of the cap and ring. The obtained single cell suspensions of the cap and ring were fixed using a fixative (manufactured by BD, CytoFix) to obtain samples for FACS. The samples for FACS were blocked and perforated using serum-containing Perm / Wash solution (BD), and immunostained with the following fluorescently labeled antibodies: anti-Chx10 antibody (Santa Cruz), anti-Crx antibody (Santa Cruz), and anti-SSEA-4 antibody. Isotype control was used as a negative control for immunostaining. Then, analysis was performed by flow cytometry using an analyzer (BD). The percentages of Chx10-positive cells, Crx-positive cells, and SSEA-4-positive cells were calculated as the difference from the respective isotype controls. The results are shown in Table 16. [Table 16]
[0266] In the cap sample, the percentage of cells positive for the neural retinal progenitor cell marker Chx10 was 29.4%, the percentage of cells positive for the photoreceptor progenitor cell marker Crx was 21.7%, and the percentage of cells positive for the pluripotent stem cell marker SSEA-4 (unintended cells) was less than 1%.In the ring sample, the percentage of cells positive for the neural retinal progenitor cell marker Chx10 was 28.1%, the percentage of cells positive for the photoreceptor progenitor cell marker Crx was 15.8%, and the percentage of cells positive for the pluripotent stem cell marker SSEA-4 (unintended cells) was less than 1%.
[0267] From these results, first, it was found that the cap sample and the ring sample were neural retina containing Chx10-positive cells and Crx-positive cells, and did not substantially contain undifferentiated iPS cells. It was also demonstrated that the ratio of Chx10-positive cells and Crx-positive cells in the cap sample was equivalent to that of Chx10-positive cells and Crx-positive cells in the ring sample. It was also demonstrated that if the ring sample was neural retina, then the cap was also neural retina.
[0268] Furthermore, it was found that when these caps or rings (preferably caps) are used as a neural retinal sheet for transplantation, the Chx10 positive cell fraction (neural retinal progenitor cell fraction) contained in this neural retinal sheet for transplantation is approximately 30% (approximately 20-40%), and the Crx positive cell fraction (photoreceptor precursor cell fraction) is approximately 17% (approximately 10-30%).
[0269] In this study, we have demonstrated the usefulness of quantitative PCR for evaluating multiple samples and multiple genes as a quality assessment method, but we also found that quality assessment can also be performed using flow cytometry analysis, which is an immunostaining method.
[0270] From the above results, it was found that in cell aggregates containing epithelial tissue with an epithelial structure (preferably neuroepithelium, more preferably neural retina), the quality of the cap can be guaranteed by isolating the cap and ring from one epithelial structure and testing the gene expression of the ring. It was found that the method for testing gene expression, whether it be quantitative PCR or immunostaining, is useful. It was also found that this quality testing methodology can be applied to epithelial tissue with an epithelial structure, whether it is neural retina or non-neural retina. [Industrial Applicability]
[0271] According to the present invention, it is possible to provide a method for evaluating the quality of a neural retina for transplantation and a neural retina sheet for transplantation selected by said method.
Claims
1. 1. A method for assessing the quality of a neural retina for transplantation, comprising: The method comprises: Extracting a part or the whole of a cell aggregate including a neural retina having an epithelial structure derived from pluripotent stem cells as a quality assessment sample; Detecting expression of neural retinal cell-related genes and non-neural retinal cell-related genes in the quality assessment sample; and determining that the neural retina (neural retina for transplantation) in the same cell aggregate as the cell aggregate containing the part of the quality assessment sample can be used as a neural retina for transplantation when expression of the neural retinal cell-related gene is observed and expression of the non-neural retinal cell-related gene is not observed. The non-neural retinal cell-related gene includes one or more genes selected from the group consisting of a telencephalon marker gene, a spinal cord marker gene, and an eyeball-related tissue marker gene. The neural retinal cell-related gene comprises one or more genes selected from the group consisting of Rax, Chx10, SIX3, SIX6, RCVRN, CRX, NRL, NESTIN, RXRG, NRL, and Blimp1; the telencephalon marker gene comprises one or more genes selected from the group consisting of FoxG1, Emx2, Dlx2, Dlx1, and Dlx5; the spinal cord marker gene comprises one or more genes selected from the group consisting of HOXD4, HOXD3, HOXD1, HOXC5, HOXA5 and HOXB2; The eye-related tissue marker gene comprises one or more genes selected from the group consisting of GREM1, GPR17, ACVR1C, CDH6, Pax2, Pax8, GAD2, SEMA5A, Zic1, MAL, HNF1beta, FoxQ1, CLDN2, CLDN1, GPR177, AQP1, AQP4, CRYAA, CRYBA1, MITF, TTR, and BEST1; A method in which, in the cell aggregate, the neural retina for transplantation is a portion near the center of a continuous epithelial tissue including the neural retina, the quality assessment sample is a ring-shaped portion of the continuous epithelial tissue that is continuous with the neural retina for transplantation, the neural retina for transplantation has a long axis of 600 μm to 2500 μm, a short axis of 200 μm to 1500 μm, and a height of 100 μm to 1000 μm, and the height of the quality assessment sample is 100 μm to 1000 μm.
2. The non-neural retinal cell-related gene further comprises a diencephalon / mesencephalon marker gene, The method of claim 1, wherein the diencephalon / mesencephalon marker genes include one or more genes selected from the group consisting of DMBX1, Nkx2.1, OTP, FGFR2, EFNA5 and GAD1.
3. The method described in claim 1 or 2, wherein the non-neural retinal cell-related genes further comprise undifferentiated pluripotent stem cell marker genes, and the undifferentiated pluripotent stem cell marker genes comprise one or more genes selected from the group consisting of Oct3 / 4, Nanog and Lin28.
4. A method according to any one of claims 1 to 3, wherein, when expression of the neural retinal cell-related genes is observed and expression of the non-neural retinal cell-related genes is not observed, the neural retina that is at least partially continuous or adjacent to a portion of the same cell aggregate as the cell aggregate containing the quality assessment sample, which is the portion, is determined to be usable as a neural retina for transplantation.
5. The method described in claim 4, wherein the neural retina for transplantation is contained in the same epithelial tissue as the quality assessment sample.
6. The cell aggregate containing the neural retina comprises a first epithelial tissue containing the neural retina for transplantation, and a second epithelial tissue having a continuity of tangent slope at a surface different from the continuity of tangent slope at a surface of the first epithelial tissue and containing non-neural retinal cells; the neural retina for transplantation comprises an area on the first epithelium furthest from the second epithelium; The method according to claim 4 or 5, wherein the quality assessment sample is a portion present between the second epithelial tissue and the neural retina for transplantation.
7. The method described in claim 6, wherein the second epithelial tissue is eye-related tissue and / or cerebrospinal tissue.
8. The method described in claim 7, wherein the eye-related tissue includes retinal pigment epithelial cells and ciliary body.
9. A method according to any one of claims 1 to 8, wherein detection of expression of the neural retinal cell-related genes and the non-neural retinal cell-related genes is performed by quantitative PCR.
10. The method described in claim 9, comprising determining that the tissue can be used as a neural retina for transplantation if the following criteria 1 and 2 are met. Criterion 1: The difference (ΔCt value) between the threshold cycle (Ct) value of the neural retinal cell-related gene and the Ct value of the internal standard gene is 10 or less. Criterion 2: The difference (ΔCt value) between the Ct value of the non-neural retinal cell-related gene and the Ct value of the internal standard gene is 5 or more
11. The method described in claim 9 or 10, wherein the quantitative PCR is performed by a method including the following steps (1) to (5), thereby simultaneously detecting the expression levels of each of neural retinal cell-related genes and non-neural retinal cell-related genes in two or more of the quality assessment samples. (1) Preparing a flow path plate having a sample well group consisting of one group of 8 to 800 independent sample wells, a primer well group consisting of one or more groups of 8 to 800 independent primer wells, and flow paths connecting the independent sample wells in the sample well group and the independent primer wells in each primer well group, a solution containing nucleic acids obtained from two or more of the quality assessment samples (sample solution), and a solution containing one or more primers specific to one or more of the neural retinal cell-associated genes or the non-neural retinal cell-associated genes (primer solution). (2) Adding the sample solution to each of the quality evaluation samples to a group of sample wells so that one sample solution is added to each of the sample wells. (3) adding the primer solution to one or more primer wells in the one or more primer well groups so that the primer wells are in different primer well groups; (4) Separately mixing the primer with the nucleic acid through the flow path. (5) Perform quantitative PCR using the mixture obtained in (4).
12. Extracting a quality assessment sample, which is a part of a cell aggregate, from each of 2 to 800 cell aggregates including a neural retina having an epithelial structure derived from pluripotent stem cells; Evaluating the extracted 2 to 800 quality assessment samples by the method according to any one of claims 1 to 11, and selecting neural retina for transplantation that is determined to be usable as neural retina for transplantation; and Isolating the selected neural retina for transplantation. A method for producing a neural retinal sheet comprising the steps of:
13. The cell aggregate is a cell aggregate comprising at least a first epithelial tissue and a second epithelial tissue, obtained by inducing differentiation of pluripotent stem cells, wherein the first epithelial tissue comprises human neural retina, and the second epithelial tissue has a continuity of tangent slope on the surface that is different from the continuity of tangent slope on the surface of the first epithelial tissue, and comprises non-neural retinal cells; The isolation of the neural retina for transplantation is performed from the cell aggregate such that the neural retina for transplantation includes a region on the first epithelium that is furthest from the second epithelium. The method of claim 12.
